To O
eliminate O
phlegm B-PHE
( O
Powder O
insufflation O
for O
pharyngitis B-PHE
and O
diphtheria B-PHE
) O
. O

-DOCSTART- O


NRP409 O
is O
presumed O
to O
work O
like O
the O
endogenous O
thyroid B-PHE
hormone I-PHE
thyroxine B-PHE
( O
T O
4 O
, O
a O
tetra-iodinated O
tyrosine O
derivative O
) O
. O

In O
the O
liver B-PHE
and O
kidney B-PHE
, O
T O
4 O
is O
converted O
to O
T O
3, O
the O
active O
metabolite B-PHE
. O

In O
order O
to O
increase O
solubility O
, O
the O
thyroid B-PHE
hormones I-PHE
attach O
to O
thyroid O
hormone O
binding O
proteins O
, O
thyroxin-binding B-PHE
globulin I-PHE
, O
and O
thyroxin-binding B-PHE
prealbumin I-PHE
( O
transthyretin B-PHE
) O
. O

Transport O
and O
binding O
to O
thyroid O
hormone O
receptors O
in O
the O
cytoplasm O
and O
nucleus O
then O
takes O
place O
. O

Thus O
by O
acting O
as O
a O
replacement O
for O
natural O
thyroxine B-PHE
, O
symptoms O
of O
thyroxine B-PHE
deficiency I-PHE
are O
relieved O
. O

-DOCSTART- O


cold B-PHE
sweating I-PHE
at O
night O

-DOCSTART- O


To O
lower O
blood B-PHE
pressure I-PHE
, O
supplement O
liver B-PHE
and O
kidney B-PHE
, O
strengthen O
sinews B-PHE
and O
bones B-PHE
, O
quiet O
fetus O
. O

-DOCSTART- O


edema B-PHE

-DOCSTART- O


high B-PHE
fever I-PHE
due O
to O
shaking B-PHE
chills I-PHE
during O
fever B-PHE

-DOCSTART- O


pain B-PHE
with O
1 O
hernia B-PHE
2 O
diseases B-PHE
of I-PHE
genitalia I-PHE
3 O
. O
severe O
pain B-PHE
in I-PHE
the I-PHE
lower I-PHE
abdomen I-PHE

-DOCSTART- O


Both O
tolterodine O
and O
its O
active O
metabolite O
, O
5-hydroxymethyltolterodine O
, O
act O
as O
competitive O
antagonists O
at O
muscarinic O
receptors O
. O

This O
antagonism O
results O
in O
inhibition O
of O
bladder B-PHE
contraction I-PHE
, O
decrease O
in O
detrusor B-PHE
pressure I-PHE
, O
and O
an O
incomplete O
emptying O
of O
the O
bladder B-PHE
. O

-DOCSTART- O


regulate O
menstruation B-PHE

-DOCSTART- O


To O
promote O
contraction O
and O
stem O
desertion O
, O
disperse O
swelling B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


smallpox B-PHE

-DOCSTART- O


profuse B-PHE
metrorrhagia I-PHE

-DOCSTART- O


Treatment O
of O
bdominal O
pain B-PHE
and O
constipation B-PHE
due O
to O
cold B-PHE
or O
retention B-PHE
of I-PHE
food I-PHE
in O
the O
intestines O
. O

-DOCSTART- O


suffering B-PHE
from O
diarrhea B-PHE
and O
having O
a O
stomachache B-PHE

-DOCSTART- O


To O
regulate O
cold B-PHE
and O
heat B-PHE
, O
regulate O
the O
functions B-PHE
of I-PHE
the I-PHE
stomach I-PHE
and O
lower O
down O
the O
adverse O
rising O
energy O
. O

-DOCSTART- O


cataract B-PHE
and O
nebula B-PHE

-DOCSTART- O


Used O
principally O
as O
an O
analgesic O
. O

-DOCSTART- O


Retention O
of O
moisture O
, O
dermatological B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE
caused O
by O
heat B-PHE
toxin I-PHE

-DOCSTART- O


dispel O
wind B-PHE

-DOCSTART- O


General O
woman O
, O
Woman O
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Leukemia B-PHE

-DOCSTART- O


injury B-PHE
by I-PHE
knife I-PHE

-DOCSTART- O


Atopic B-PHE
Dermatitis I-PHE

-DOCSTART- O


Chinese O
herbal O
medicine O
( O
CHM O
) O
, O
either O
in O
single O
herb O
or O
in O
herbal O
formula O
, O
has O
been O
used O
to O
treat O
insomnia B-PHE
for O
more O
than O
2000 O
years O
. O

A O
systematic O
review O
including O
Chinese O
and O
English O
literature O
of O
randomized O
controlled O
trials O
was O
conducted O
to O
examine O
the O
efficacy O
, O
safety O
, O
and O
composition O
of O
CHM O
for O
insomnia B-PHE
. O

Among O
the O
217 O
studies O
we O
have O
reviewed O
, O
only O
eight O
had O
a O
Jadad O
score O
>= O
3, O
and O
seven O
out O
of O
these O
eight O
studies O
had O
at O
least O
one O
domain O
with O
high O
risks O
of O
bias O
. O

Meta-analyses O
of O
the O
studies O
with O
Jadad O
score O
>= O
3 O
found O
that O
CHM O
was O
similar O
to O
Western O
medication O
( O
three O
studies O
) O
and O
placebo O
( O
three O
studies O
) O
in O
treating O
insomnia B-PHE
. O

Due O
to O
the O
poor O
methodological O
quality O
of O
the O
studies O
and O
the O
small O
number O
of O
trials O
included O
in O
meta-analyses O
, O
the O
current O
evidence O
is O
insufficient O
to O
support O
the O
efficacy O
of O
CHM O
for O
insomnia B-PHE
. O

The O
frequency O
of O
adverse O
events O
associated O
with O
CHM O
was O
similar O
to O
that O
of O
placebo O
, O
but O
lower O
than O
with O
Western O
medication O
. O

Gui O
Pi O
Tang O
was O
the O
most O
commonly O
used O
standardized O
formula O
, O
while O
Suan O
Zao O
Ren O
( O
Ziziphus O
jujuba O
) O
was O
the O
most O
frequently O
used O
single O
herb O
. O

Further O
studies O
with O
a O
double-blind O
placebo-controlled O
design O
are O
needed O
to O
accurately O
determine O
the O
benefits O
and O
risks O
of O
CHM O
for O
insomnia B-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
disinhibit O
water O
and O
harmonize O
center O
, O
quicken O
blood B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


disharmony B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
stomach I-PHE
a O
morbid B-PHE
condition I-PHE
marked O
by O
poor B-PHE
appetite I-PHE
, O
loose B-PHE
stools I-PHE
and O
other O
symptoms O
of O
indigestion B-PHE
. O

-DOCSTART- O


For O
stablizing O
period O
, O
controlling O
urine B-PHE
and O
reducing O
heavy B-PHE
blood-flow I-PHE

-DOCSTART- O


refers O
to O
the O
dream-disturbed O
sleep O

-DOCSTART- O


Enzalutamide O
is O
indicated O
for O
the O
treatment O
of O
patients O
with O
metastatic B-PHE
castration-resistant I-PHE
prostate I-PHE
cancer I-PHE
who O
have O
previously O
received O
docetaxel O
. O

-DOCSTART- O


protracted O
dysentery B-PHE
; O
chronic B-PHE
dysentery I-PHE
; O
prolonged O
dysentery B-PHE

-DOCSTART- O


Chronic B-PHE
Renal I-PHE
Failure I-PHE

-DOCSTART- O


Respiratory B-PHE
Distress I-PHE

-DOCSTART- O


infraumbilical B-PHE
cold I-PHE
pain I-PHE

-DOCSTART- O


It O
means O
not O
shiny O
hair O

-DOCSTART- O


Malaria B-PHE
infection I-PHE

-DOCSTART- O


ulcerative B-PHE
gingivitis I-PHE

-DOCSTART- O


Asthma B-PHE

-DOCSTART- O


vomiting B-PHE
due O
to O
heat B-PHE
in O
the O
stomach O

-DOCSTART- O


To O
tonify O
Qi O
and O
strengthen O
the O
spleen B-PHE
. O

To O
consolidate O
the O
Chong B-PHE
channel I-PHE
and O
control O
the O
blood B-PHE
. O

-DOCSTART- O


ETI-204 O
is O
an O
affinity-enhanced O
, O
de-immunized O
antibody O
, O
which O
means O
that O
its O
ability O
to O
bind O
to O
its O
target O
pathogen O
has O
been O
strengthened O
and O
that O
elements O
that O
might O
cause O
an O
immune B-PHE
response I-PHE
have O
been O
removed O
. O

ETI-204 O
targets O
and O
binds O
to O
Protective O
Antigen O
, O
which O
prevents O
the O
anthrax B-PHE
toxins I-PHE
from O
binding O
to O
and O
entering O
the O
cells O
in O
the O
body O
, O
thereby O
preventing O
death B-PHE
. O

-DOCSTART- O


Emergence B-PHE
Agitation I-PHE

-DOCSTART- O


Muscle B-PHE
Weakness I-PHE

-DOCSTART- O


Didanosine O
is O
converted O
to O
the O
active O
triphosphate O
form O
, O
which O
is O
incorporated O
into O
DNA O
and O
inhibits O
DNA B-PHE
elongation I-PHE
. O

-DOCSTART- O


Colonic B-PHE
Cancer I-PHE
. O

-DOCSTART- O


menorrhagia B-PHE
; O
abnormally O
profuse B-PHE
menstruation I-PHE

-DOCSTART- O


Lymphoma B-PHE
, I-PHE
Non-Hodgkin I-PHE

-DOCSTART- O


Cholangiocarcinoma B-PHE

-DOCSTART- O


affection O
due O
to O
wind-heat B-PHE
; O
common O
cold B-PHE
of O
the O
wind-heat B-PHE
type O
; O
flu B-PHE
caused O
by O
wind B-PHE
and O
heat B-PHE

-DOCSTART- O


Pralnacasan O
inhibits O
interleukin-1beta B-PHE
converting I-PHE
enzyme I-PHE
( O
ICE B-PHE
) O
, O
an O
enzyme B-PHE
that O
regulates O
the O
production B-PHE
of I-PHE
IL-1 I-PHE
and I-PHE
IFN I-PHE
gamma I-PHE
- I-PHE
intercellular I-PHE
mediators I-PHE
that O
initiate O
and O
sustain O
the O
process O
of O
inflammation B-PHE
. O

Inhibiting O
ICE B-PHE
may O
be O
an O
effective O
strategy O
for O
curtailing O
damaging O
inflammatory O
processes O
common O
to O
a O
number O
of O
acute O
and O
chronic O
conditions O
, O
such O
as O
rheumatoid B-PHE
arthritis I-PHE
( O
RA B-PHE
) O
and O
osteoarthritis B-PHE
. O

-DOCSTART- O


Treatment O
of O
edema B-PHE
, O
oliguria B-PHE
, O
arthritis B-PHE
with O
contracture B-PHE
of O
joints O
, O
diarrhea B-PHE
due O
to O
diminished B-PHE
function I-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
lung B-PHE
abscess I-PHE
, O
appendicitis B-PHE
, O
verruca B-PHE
plana I-PHE
. O

-DOCSTART- O


Epinastine O
has O
a O
multiaction O
effect O
that O
inhibits O
the O
allergic B-PHE
response I-PHE
in O
3 O
ways O
: O
1 O
stabilizes O
mast B-PHE
cells I-PHE
by O
preventing O
mast B-PHE
cell I-PHE
degranulation I-PHE
to O
control O
the O
allergic B-PHE
response I-PHE
, O
2 O
prevents O
histamine B-PHE
binding O
to O
both O
the O
H1- O
and O
H O
2-receptors O
to O
stop O
itching B-PHE
and O
provide O
lasting B-PHE
protection I-PHE
, O
and O
3 O
prevents O
the O
release B-PHE
of I-PHE
proinflammatory I-PHE
chemical I-PHE
mediators I-PHE
from O
the O
blood B-PHE
vessel I-PHE
to O
halt O
progression O
of O
the O
allergic B-PHE
response I-PHE
. O

-DOCSTART- O


Parkinsons B-PHE
Disease I-PHE

-DOCSTART- O


1 O
For O
cases O
with O
paralysis B-PHE
of I-PHE
lower I-PHE
limbs I-PHE
and O
feverish B-PHE
sensation I-PHE
of O
joints O
, O
which O
are O
attritbutive O
to O
deficiency O
of O
kidney-yin O
, O
omit O
menthae O
, O
Ziziphi O
jujubae O
and O
add O
carapax O
trionycis O
and O
ramulus O
mori O
to O
benefit O
kidney-yin O
and O
eliminate O
asthenic B-PHE
heat I-PHE
. O

-DOCSTART- O


cold B-PHE
and O
heat B-PHE
; O

cold B-PHE
syndrome I-PHE
and O
heat B-PHE
syndrome I-PHE
two O
of O
the O
eight O
principles O
in O
analysing O
and O
differentiating O
pathological O
conditions O
; O

cold B-PHE
caused O
by O
excess O
of O
Eum O
, O
and O
heat B-PHE
caused O
by O
excess O
of O
Yang O
. O

chills B-PHE
and O
fever B-PHE

cold B-PHE
pathogene I-PHE
and O
heat B-PHE
pathogene I-PHE

-DOCSTART- O


retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
; O
dyspepsia B-PHE

-DOCSTART- O


Adult B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


promote O
menstruation B-PHE

-DOCSTART- O


stop O
thirst B-PHE

-DOCSTART- O


weakness B-PHE
of O
the O
waist O

-DOCSTART- O


terminate O
lactation B-PHE

-DOCSTART- O


To O
relieve O
cough B-PHE
and O
promote O
expectoration B-PHE
, O
to O
promote O
digestion B-PHE
and O
remove O
stagnancy B-PHE
of I-PHE
food I-PHE
, O
and O
to O
promote O
blood B-PHE
circulation I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Metformin O
acts O
by O
the O
initial O
activation B-PHE
of I-PHE
AMP-activated I-PHE
protein I-PHE
kinase I-PHE
( O
AMPK O
) O
, O
a O
liver B-PHE
enzyme I-PHE
that O
plays O
an O
important O
role O
in O
insulin B-PHE
signaling I-PHE
, O
whole B-PHE
body I-PHE
energy I-PHE
balance I-PHE
, O
and O
the O
metabolism B-PHE
of I-PHE
glucose I-PHE
and I-PHE
fats I-PHE
. O

Pioglitazone O
activates O
peroxisome B-PHE
proliferator-activated I-PHE
receptor I-PHE
gamma I-PHE
( O
PPAR-gamma B-PHE
) O
, O
a O
ligand-activated B-PHE
transcription I-PHE
factor I-PHE
, O
thereby O
inducing O
cell B-PHE
differentiation I-PHE
and O
inhibiting O
cell B-PHE
growth I-PHE
and O
angiogenesis B-PHE
. O

-DOCSTART- O


food B-PHE
damage I-PHE
; O

injury B-PHE
due O
to O
improper O
diet O
; O

eating O
food O
much O
injury B-PHE
of O
spleen O
and O
stomach O

-DOCSTART- O


The O
authors O
report O
the O
3 O
months O
treatment O
of O
51 O
cases O
of O
breast B-PHE
proliferation I-PHE
disease I-PHE
with O
modified O
Xiao O
Yao O
San O
and O
Er O
Chen O
decoction O
, O
an O
effective O
rate O
being O
0.961 O
. O

In O
each O
patient O
before O
and O
after O
treatment O
, O
saliva B-PHE
estradiol I-PHE
( O
SE2 B-PHE
) O
, O
saliva B-PHE
progesterone I-PHE
( O
SP B-PHE
) O
, O
saliva B-PHE
testosterone I-PHE
( O
ST B-PHE
) O
and O
plasma B-PHE
prolactin I-PHE
( O
PRL B-PHE
) O
concentrations O
were O
monitored O
and O
breast O
molybdenum O
- O
target O
X O
- O
ray O
films O
were O
taken O
. O

The O
results O
showed O
that O
after O
treatment O
, O
SE2 B-PHE
concentrations I-PHE
declined O
very O
significantly O
( O
P O
less O
than O
0.001 O
) O
; O
SP B-PHE
concentrations I-PHE
declined O
significantly O
( O
P O
less O
than O
0.05 O
) O
; O
PRL B-PHE
concentrations I-PHE
declined O
very O
significantly O
( O
P O
less O
than O
0.005 O
) O
, O
but O
ST B-PHE
concentrations I-PHE
did O
not O
change O
significantly O
. O

Breast O
molybdenum O
- O
target O
X O
- O
ray O
films O
showed O
absorption O
of O
proliferation O
masses O
in O
21 O
cases O
. O

These O
indicated O
that O
the O
medicine O
could O
regulate O
endocrine B-PHE
system I-PHE
, O
perhaps O
through O
suppressing O
secretion B-PHE
of I-PHE
PRL I-PHE
, O
decreasing O
prolactin B-PHE
antagonist I-PHE
action I-PHE
to O
follicular B-PHE
stimulating I-PHE
hormone I-PHE
so O
as O
to O
restore O
follicle B-PHE
function I-PHE
, O
and O
could O
regulate O
pituitary O
- O
follicle O
axis O
and O
make O
the O
axis O
normal O
. O

-DOCSTART- O


To O
enrich O
yin O
and O
supplement O
kidney B-PHE
, O
clear O
lung B-PHE
and O
moisten O
dryness B-PHE
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


stomachache B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE
( O
M7 B-PHE
) O

-DOCSTART- O


To O
transform O
dampness B-PHE
and O
promote O
water B-PHE
metabolism I-PHE
. O

-DOCSTART- O


yellowish B-PHE
complexion I-PHE

-DOCSTART- O


Seasonal B-PHE
Allergic I-PHE
Rhinitis I-PHE

-DOCSTART- O


relieve O
Clonorchiasis B-PHE
toxin I-PHE

-DOCSTART- O


wind-toxic B-PHE
pathogen O

-DOCSTART- O


Binding O
of O
dalbavancin O
to O
the O
D-Ala-D-Ala O
prevents O
the O
incorporation O
of O
the O
NAM/NAG-peptide O
subunits O
into O
the O
peptidoglycan O
matrix O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
remove O
obstruction O
of O
the O
collaterals O
, O
and O
relieve O
spasms B-PHE
and O
convulsions B-PHE
. O

-DOCSTART- O


a O
symptom O
of O
fingers B-PHE
being I-PHE
cold I-PHE
although O
the O
temperature O
is O
not O

-DOCSTART- O


disperse O
carbuncle B-PHE
swelling B-PHE

-DOCSTART- O


For O
bacterial B-PHE
infections I-PHE
of O
eyes O

-DOCSTART- O


function O

-DOCSTART- O


Reserpine's O
mechanism O
of O
action O
is O
through O
inhibition O
of O
the O
ATP/Mg2+ O
pump O
responsible O
for O
the O
sequestering O
of O
neurotransmitters B-PHE
into O
storage O
vesicles O
located O
in O
the O
presynaptic B-PHE
neuron I-PHE
. O

Trichlormethiazide O
appears O
to O
block O
the O
active O
reabsorption O
of O
chloride O
and O
possibly O
sodium O
in O
the O
ascending O
loop B-PHE
of I-PHE
Henle I-PHE
, O
altering O
electrolyte O
transfer O
in O
the O
proximal B-PHE
tubule I-PHE
. O

-DOCSTART- O


Pain B-PHE
Due O
to O
Certain O
Specified O
Procedures O

-DOCSTART- O


Juvenile B-PHE
Idiopathic I-PHE
Arthritis I-PHE

-DOCSTART- O


To O
transform O
water O
and O
reduce O
edema B-PHE

-DOCSTART- O


dispel O
wind B-PHE
and O
eliminate O
dampness B-PHE

-DOCSTART- O


Treatment O
of O
deficiency B-PHE
condition I-PHE
of I-PHE
the I-PHE
kidney I-PHE
marked O
by O
lumbago B-PHE
and O
lack B-PHE
of I-PHE
strength I-PHE
, O
threatened B-PHE
abortion I-PHE
, O
hypertension B-PHE
. O

-DOCSTART- O


pain B-PHE
of O
genitals O
among O
men O
and O
women O

-DOCSTART- O


Heat B-PHE
vexation I-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
vomiting B-PHE
nausea I-PHE
, O
vacuity B-PHE
heat I-PHE
cough I-PHE
, O
dry B-PHE
stool I-PHE
, O
swelling B-PHE
of I-PHE
welling I-PHE
abscess I-PHE
, O
welling B-PHE
abscess I-PHE
and O
flat B-PHE
abscess I-PHE
with O
swelling B-PHE
sore I-PHE
. O

-DOCSTART- O


Treament O
of O
edema B-PHE
or O
retained O
fluid O
with O
abdominal B-PHE
distension I-PHE
, O
oliguria B-PHE
and O
constipation B-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
external O
use O
for O
ringworm B-PHE
and O
verrucous B-PHE
vegetations I-PHE
. O

-DOCSTART- O


1 O
An O
active O
component O
, O
anisaldehyde O
, O
increases O
the O
effect O
of O
streptomycin B-PHE
on O
experimental O
tuberculosis B-PHE
in O
mice O
. O
Accelerating O
gastrointestinal B-PHE
peristalsis I-PHE
, O
and O
promoting O
eliminating B-PHE
of I-PHE
flatus I-PHE
. O
Eliminating O
phlegm B-PHE
. O

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
short B-PHE
, I-PHE
rapid I-PHE
and I-PHE
interrupted I-PHE
breathing I-PHE
. O

-DOCSTART- O


neck B-PHE
stiffness I-PHE
; O
neck B-PHE
rigidity I-PHE
; O
rigidity B-PHE
of I-PHE
the I-PHE
neck I-PHE
; O
rigid B-PHE
neck I-PHE

-DOCSTART- O


Beginning O
stage O
of O
rash B-PHE
, O
fever B-PHE
, O
cough B-PHE
, O
alternating O
cold B-PHE
and I-PHE
hot I-PHE
feeling I-PHE

-DOCSTART- O


mania-withdrawal B-PHE
; O

mania B-PHE
; O

manic-depressive B-PHE
psychosis I-PHE

-DOCSTART- O


Yokukansan O
inhibits O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
: O
the O
role O
of O
a O
A-adrenoceptor B-PHE
. O

-DOCSTART- O


Milnacipran O
is O
used O
to O
treat O
moderate O
to O
severe O
clinical B-PHE
depression I-PHE
but O
this O
indication O
is O
not O
yet O
FDA-approved O
in O
the O
USA O
. O

Milnacipran O
is O
labelled O
for O
the O
treatment O
of O
fibromyalgia B-PHE
pain I-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
soothe O
sinews O
and O
quicken O
blood B-PHE
, O
relieve O
cough B-PHE
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Neuromyelitis B-PHE
Optica I-PHE
( O
NMO B-PHE
) O

-DOCSTART- O


Treatment O
of O
pains B-PHE
caused O
by O
blood B-PHE
stagnation I-PHE
. O

-DOCSTART- O


Berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic B-PHE
cancer I-PHE
and O
lymphoma B-PHE
. O

-DOCSTART- O


Rikkunshito O
improves O
globus B-PHE
sensation I-PHE
in O
patients O
with O
proton-pump O
inhibitor-refractory O
laryngopharyngeal B-PHE
reflux I-PHE
. O

-DOCSTART- O


Treatment O
of O
stagnation O
of O
qi O
in O
the O
liver B-PHE
and O
stomach B-PHE
manifested O
by O
distending O
pain B-PHE
in O
the O
chest O
and O
hypochodria B-PHE
, O
fullness B-PHE
and O
stuffiness B-PHE
sensation O
in O
the O
epigastrium O
, O
vomiting B-PHE
and O
belching B-PHE
, O
cough B-PHE
with O
copious O
expectoration B-PHE
. O

-DOCSTART- O


To O
induce O
subsidence O
of O
swelling B-PHE
and O
remove O
toxic B-PHE
substances O
, O
to O
cause O
purgation B-PHE
. O

-DOCSTART- O


papule B-PHE

-DOCSTART- O


stop O
itching B-PHE

-DOCSTART- O


Parkinson B-PHE
Disease I-PHE

-DOCSTART- O


Treatment O
of O
impotence B-PHE
and O
seminal O
emission O
, O
mass B-PHE
in O
the O
abdomen B-PHE
, O
scrofula B-PHE
, O
traumatic B-PHE
injuries I-PHE
, O
external O
use O
for O
carbuncles B-PHE
and O
boils O
. O

-DOCSTART- O


This O
is O
a O
syndrome O
with O
palpitation B-PHE
and O
severe O
palpitation B-PHE
. O

-DOCSTART- O


harmonize O
acute B-PHE
and I-PHE
chronic I-PHE
disease I-PHE
of O
center O

-DOCSTART- O


epigastric O
fullness O
; O
stuffiness B-PHE
in O
the O
gastric O
region O

-DOCSTART- O


In O
order O
to O
investigate O
the O
characteristic O
of O
optical O
properties O
of O
Asian O
dust O
particles O
, O
the O
atmospheric O
aerosol O
vertical O
profile O
was O
measured O
with O
the O
multi-wavelength O
LIDAR O
system O
, O
at O
the O
Gosan O
super O
site O
( O
33 O
degrees O
17'N O
, O
126 O
degrees O
10'E O
) O
in O
Jeju O
Island O
, O
Korea O
, O
during O
the O
ACE-Asia O
intensive O
observation O
period O
, O
11 O
42798 O
May O
2001 O
. O

An O
air O
mass O
backward O
trajectory O
analysis O
, O
using O
Hysplit-4 O
, O
was O
carried O
out O
to O
track O
the O
aerosol O
plume O
, O
with O
high O
mass O
loading O
, O
from O
the O
Chinese O
desert O
regions O
during O
the O
period O
of O
Asian O
dust O
storm O
events O
. O

Vertical O
atmospheric O
aerosol O
profiles O
on O
three O
major O
Asian O
dust O
storm O
event O
days O
, O
22 O
March O
and O
13 O
and O
26 O
April O
2001 O
, O
have O
been O
analyzed O
. O

The O
LIDAR-derived O
aerosol O
optical O
depth O
values O
were O
compared O
with O
those O
measured O
by O
a O
collocated O
sunphotometer O
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
cataracts B-PHE
, O
eye B-PHE
disorders I-PHE
/ I-PHE
infections I-PHE
, O
glaucoma B-PHE
, O
and O
macular B-PHE
degeneration I-PHE
. O

-DOCSTART- O


Baker's B-PHE
Cyst I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Others O

-DOCSTART- O


prolapse B-PHE
of I-PHE
uterus I-PHE

-DOCSTART- O


the O
disease B-PHE
that O
liver O
and O
spleen O
become O
swollen B-PHE
and O
enlarged B-PHE

-DOCSTART- O


release O
muscles B-PHE

-DOCSTART- O


arthralgia B-PHE
and O
myalgia B-PHE
; O
pain B-PHE
in O
the O
muscles O
and O
bones O

-DOCSTART- O


the O
heat B-PHE
syndrome I-PHE
syndrome O
due O
to O
attack O
of O
pathogenic O
heat B-PHE
or O
hyperactivity B-PHE
of O
Yanggi O
, O
usually O
seen O
in O
infectious B-PHE
disease I-PHE
and O
those O
caused O
by O
abnormal O
hyperactivity I-PHE
of O
the O
body O
, O
with O
manifestation O
such O
as O
fever B-PHE
, O
fidgets B-PHE
, O
flushed B-PHE
face I-PHE
, O
congested B-PHE
eyes I-PHE
dry B-PHE
mouth I-PHE
and I-PHE
throat I-PHE
, O
red O
and O
dry B-PHE
lip I-PHE
thirst B-PHE
with O
preference O
for O
cold O
drink O
, O
constipation B-PHE
, O
scanty O
dark B-PHE
urine I-PHE
reddened B-PHE
tongue I-PHE
with O
dry B-PHE
brow I-PHE
or O
black O
coating O
, O
and O
rapid B-PHE
pulse I-PHE
. O

-DOCSTART- O


spitting B-PHE
pus I-PHE
and I-PHE
blood I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
obesity B-PHE
. O

-DOCSTART- O


the O
low B-PHE
back I-PHE
and I-PHE
knees I-PHE
being I-PHE
aching I-PHE
and I-PHE
limp I-PHE
( O
i O
. O
e O
. O
, O
weak O
) O

-DOCSTART- O


To O
dispel O
damp B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


SP-01A O
is O
an O
HIV B-PHE
oral O
entry O
inhibitor O
drug O
. O

In O
order O
for O
viruses B-PHE
to O
reproduce O
, O
they O
must O
infect O
or O
hi-jack O
a O
cell O
, O
and O
use O
it O
to O
make O
new O
viruses B-PHE
. O

Just O
as O
your O
body O
is O
constantly O
making O
new O
skin B-PHE
cells I-PHE
, O
or O
new O
blood B-PHE
cells I-PHE
, O
each O
cell O
often O
makes O
new O
proteins O
in O
order O
to O
stay O
alive O
and O
to O
reproduce O
itself O
. O

Viruses B-PHE
hide O
their O
own O
DNA O
in O
the O
DNA O
of O
the O
cell O
, O
and O
then O
, O
when O
the O
cell O
tries O
to O
make O
new O
proteins O
, O
it O
accidentally O
makes O
new O
viruses B-PHE
as O
well O
. O

HIV B-PHE
mostly O
infects O
cells O
in O
the O
immune B-PHE
system I-PHE
. O

-DOCSTART- O


Arrhythmia B-PHE

-DOCSTART- O


As O
an O
anthelmintic O
for O
tapeworm O
and O
hookworm O
, O
more O
effective O
than O
that O
of O
tetrachloroethylene O
. O

-DOCSTART- O


conjunctival B-PHE
congestion I-PHE

-DOCSTART- O


night B-PHE
blindness I-PHE
. O
Visual B-PHE
disorder I-PHE
at O
night O
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
motility B-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


bruise B-PHE

-DOCSTART- O


incised B-PHE
wound I-PHE

-DOCSTART- O


To O
relieve O
rheumatic B-PHE
conditions I-PHE
, O
to O
strengthen O
the O
tendons B-PHE
and O
bones B-PHE
, O
and O
to O
arrest O
bleeding B-PHE
. O

-DOCSTART- O


promote O
all O
vessels B-PHE

-DOCSTART- O


constrain O
the O
lung B-PHE

-DOCSTART- O


Phenylpropanolamine O
acts O
directly O
on O
alpha- O
and O
, O
to O
a O
lesser O
degree O
, O
beta-adrenergic O
receptors O
in O
the O
mucosa B-PHE
of I-PHE
the I-PHE
respiratory I-PHE
tract I-PHE
. O

-DOCSTART- O


promote O
the O
stomach B-PHE
and O
increase O
food B-PHE
intake I-PHE

-DOCSTART- O


Adult B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE
With O
t(9;22)(q34;q11.2 O
) O
; O
BCR-ABL1 O

-DOCSTART- O


Uncomplicated B-PHE
Falciparum I-PHE
Malaria I-PHE

-DOCSTART- O


Myelodysplastic B-PHE
Syndromes I-PHE

-DOCSTART- O


restlessness B-PHE
and O
thirst B-PHE
; O

polydipsia B-PHE

-DOCSTART- O


Saengmaeksan O
inhibits O
inflammatory B-PHE
mediators I-PHE
by O
suppressing O
RIP-2 B-PHE
/ I-PHE
caspase-1 I-PHE
activation I-PHE
. O

-DOCSTART- O


general O
weakness B-PHE
and O
weight B-PHE
loss I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
free O
network B-PHE
vessels I-PHE
, O
disperse O
swelling B-PHE
and O
relieve O
pain B-PHE
, O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


cooling O
throat B-PHE

-DOCSTART- O


Relief O
of O
mild O
to O
moderate O
pain B-PHE

-DOCSTART- O


Despite O
the O
development O
of O
radiotherapy O
machines O
and O
technologies O
, O
a O
proportion O
of O
patients O
suffer O
from O
radiation-induced B-PHE
lymphedema I-PHE
. O

Saireito O
( O
SRT O
) O
is O
a O
traditional O
Japanese O
herbal O
medicine O
that O
has O
been O
used O
for O
treating O
edema B-PHE
and O
inflammation B-PHE
in O
conditions O
such O
as O
nephritic B-PHE
disease I-PHE
. O

This O
study O
investigated O
the O
effect O
of O
SRT O
on O
lymphedema B-PHE
caused O
by O
radiotherapy O
. O

Four O
patients O
were O
treated O
with O
SRT O
at O
a O
dose O
of O
9 O
g/day O
. O

The O
severity O
of O
lymphedema B-PHE
was O
evaluated O
using O
the O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
version O
4 O
and O
Numerical O
Rating O
Scale O
before O
and O
after O
SRT O
treatment O
. O

After O
the O
treatment O
with O
SRT O
, O
2 O
of O
4 O
patients O
( O
0.5 O
) O
showed O
apparent O
improvement O
in O
lymphedema B-PHE
. O

One O
of O
the O
cases O
had O
difficulty O
in O
wearing O
the O
custom-made O
thermoplastic O
cast O
, O
but O
after O
SRT O
administration O
, O
he O
could O
wear O
the O
mask O
easily O
. O

One O
case O
decided O
to O
stop O
taking O
SRT O
3 O
days O
after O
initiation O
because O
cough B-PHE
and O
fever B-PHE
appeared O
. O

In O
conclusion O
, O
it O
is O
important O
to O
control O
the O
side O
effects O
of O
radiotherapy O
, O
which O
leads O
to O
improved O
tumor B-PHE
control I-PHE
rates I-PHE
. O

Prospective O
randomized O
studies O
are O
necessary O
to O
confirm O
the O
findings O
of O
this O
case O
series O
study O
. O

-DOCSTART- O


Zuo O
Jin O
Wan O
( O
ZJW O
) O
, O
a O
typical O
traditional O
Chinese O
medicine O
( O
TCM O
) O
formula O
, O
has O
been O
identified O
to O
have O
anticancer B-PHE
activity I-PHE
in O
recent O
studies O
. O

In O
this O
study O
, O
we O
determined O
the O
underlying O
mechanism O
of O
ZJW O
in O
the O
reversal O
effect O
of O
multidrug O
resistance O
on O
colorectal B-PHE
cancer I-PHE
in O
vitro O
and O
in O
vivo O
. O

Our O
results O
showed O
that O
ZJW O
significantly O
enhanced O
the O
sensitivity O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
, O
SGC7901/DDP O
, O
and O
Bel/Fu O
MDR O
cells O
. O

Moreover O
, O
combination O
of O
chemotherapy O
with O
ZJW O
could O
reverse O
the O
drug O
resistance O
of O
HCT116/L-OHP B-PHE
cells I-PHE
, O
increase O
the O
sensitivity O
of O
HCT116/L-OHP B-PHE
cells I-PHE
to O
L-OHP O
, O
DDP O
, O
5-Fu O
, O
and O
MMC O
in O
vitro O
, O
and O
inhibit O
the O
tumor B-PHE
growth I-PHE
in O
the O
colorectal O
MDR O
cancer O
xenograft O
model O
. O

ICP-MS O
results O
showed O
that O
ZJW O
could O
increase O
the O
concentration O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
cells O
in O
a O
dose-dependent O
manner O
. O

Furthermore O
, O
we O
showed O
that O
ZJW O
could O
reverse O
drug O
resistance O
of O
colorectal B-PHE
cancer I-PHE
cells O
by O
decreasing O
P-gp B-PHE
level I-PHE
in O
vitro O
and O
in O
vivo O
, O
which O
has O
been O
represented O
as O
one O
of O
the O
major O
mechanisms O
that O
contribute O
to O
the O
MDR O
phenotype O
. O

Our O
study O
has O
provided O
the O
first O
direct O
evidence O
that O
ZJW O
plays O
an O
important O
role O
in O
reversing O
multidrug O
resistance O
of O
human B-PHE
colorectal I-PHE
cancer I-PHE
and O
may O
be O
considered O
as O
a O
useful O
target O
for O
cancer O
therapy O
. O

-DOCSTART- O


To O
arrest O
bleeding B-PHE
by O
reducing O
heat B-PHE
in O
blood O
, O
to O
remove O
heat B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


syphilis B-PHE
; O
strawberry O
sores B-PHE
; O
syphilitic B-PHE
skin I-PHE
disease I-PHE

-DOCSTART- O


Appears O
to O
preferentially O
bind O
to O
mycobacterial B-PHE
DNA I-PHE
leading O
to O
disruption B-PHE
of I-PHE
the I-PHE
cell I-PHE
cycle I-PHE
and O
eventually O
kills O
the O
bacterium B-PHE
. O

-DOCSTART- O


hemiplegia B-PHE

-DOCSTART- O


the O
body O
is O
fatigued O
and O
cannot O
walk O
because O
of O
a O
flaccidity B-PHE
of I-PHE
lower I-PHE
limbs I-PHE

-DOCSTART- O


To O
warm O
the O
kidney B-PHE
and O
promote O
virility B-PHE
, O
to O
reduce O
modulation O
, O
and O
to O
induce O
subsidence O
of O
swelling B-PHE
. O

-DOCSTART- O


Croton O
seed O
( O
Badou O
) O
is O
used O
externally O
. O

-DOCSTART- O


Warfarin O
inhibits O
vitamin B-PHE
K I-PHE
reductase I-PHE
, O
resulting O
in O
depletion O
of O
the O
reduced O
form O
of O
vitamin B-PHE
K I-PHE
which O
reduces O
the O
thrombogenicity B-PHE
of I-PHE
clots I-PHE
. O

Heparin O
binds O
to O
antithrombin O
III O
to O
form O
a O
heparin-antithrombin O
III O
complex O
. O

The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin B-PHE
and O
other O
activated O
clotting B-PHE
factors I-PHE
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization B-PHE
of I-PHE
fibrinogen I-PHE
to O
fibrin O
and O
the O
subsequent O
formation B-PHE
of I-PHE
clots I-PHE
. O

-DOCSTART- O


Cholelithiasis B-PHE
, O
infection B-PHE
of I-PHE
the I-PHE
biliary I-PHE
tract I-PHE
, O
cholecystitis B-PHE
. O

-DOCSTART- O


Dermatitis B-PHE
, I-PHE
Atopic I-PHE

-DOCSTART- O


As O
GABA B-PHE
is O
an O
inhibitory O
neurotransmitter O
, O
this O
results O
in O
increased O
inhibition O
of O
the O
ascending O
reticular B-PHE
activating I-PHE
system I-PHE
. O

-DOCSTART- O


Pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-PHE
synthase I-PHE
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
DNA B-PHE
synthesis I-PHE
. O

ABT-751 O
binds O
to O
the O
colchicine-binding O
site O
on O
beta-tubulin O
and O
inhibits O
the O
polymerization O
of O
microtubules O
, O
thereby O
preventing O
tumor B-PHE
cell I-PHE
replication I-PHE
. O

-DOCSTART- O


Bacterial B-PHE
infections I-PHE
of I-PHE
the I-PHE
eyes I-PHE
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE

-DOCSTART- O


Acute B-PHE
Adrenal I-PHE
Insufficiency I-PHE

-DOCSTART- O


Inecalcitol O
is O
an O
analogue O
of O
calcitriol O
, O
the O
naturally O
active O
metabolite O
of O
vitamin O
D O
. O

Calcitriol O
and O
their O
analogues O
activate O
the O
vitamin O
D O
receptor O
( O
VDR O
) O
. O

Vitamin O
D O
has O
a O
major O
role O
in O
regulating O
calcium B-PHE
absorption I-PHE
from O
the O
gut O
, O
storage O
in O
mineral O
form O
in O
the O
bones O
, O
and O
excretion B-PHE
by O
the O
kidney O
and O
effectively O
prevents O
rickets B-PHE
in O
infants O
. O

Vitamin O
D O
and O
calcitriol O
can O
cause O
hypercalcemia B-PHE
at O
high O
or O
frequently O
repeated O
doses O
; O
in O
turn O
, O
hypercalcemia B-PHE
can O
cause O
kidney B-PHE
toxicity I-PHE
by O
accumulation O
of O
calcium-containing O
micro-crystals O
and O
heart B-PHE
and I-PHE
muscle I-PHE
dysfunction I-PHE
by O
impairing O
contractions O
. O

The O
mechanism O
of O
action O
is O
currently O
unknown O
, O
but O
it O
is O
proposed O
that O
inecalcitol O
exerts O
its O
superagonistic O
action O
through O
enhancing O
coactivator O
binding O
by O
the O
VDR O
. O

-DOCSTART- O


The O
herbal O
medicine O
Tokishakuyakusan O
increases O
fetal O
blood B-PHE
glucose I-PHE
concentrations I-PHE
and O
growth B-PHE
hormone I-PHE
levels I-PHE
and O
improves O
intrauterine B-PHE
growth I-PHE
retardation I-PHE
induced O
by O
N(omega)-nitro-L-arginine O
methyl O
ester O
. O

-DOCSTART- O


1 O
Interrupting O
pregnancy B-PHE
. O

2 O
Its O
active O
component O
, O
trichosanthin O
, O
is O
effective O
on O
placental B-PHE
trophocytic I-PHE
tumor I-PHE
. O

3 O
. O
Bacteriostatic B-PHE
. O

-DOCSTART- O


Endometrial B-PHE
Cancer I-PHE

-DOCSTART- O


promote O
the O
stomach B-PHE
and O
increased O
food B-PHE
intake I-PHE

-DOCSTART- O


Weak B-PHE
and I-PHE
reduced I-PHE
yin I-PHE
blood I-PHE
after O
treatment O
, O
exterior B-PHE
evil I-PHE
, O
loss B-PHE
of I-PHE
blood I-PHE
, O
cold B-PHE
and O
period O
, O
headache B-PHE
, O
hot B-PHE
body I-PHE
, O
feeling O
slightly O
cold B-PHE
, O
no B-PHE
sweating I-PHE
. O

-DOCSTART- O


Treatment O
of O
deficiency B-PHE
syndrome I-PHE
of O
the O
kidney O
marked O
by O
back B-PHE
pain I-PHE
, O
tinnitus B-PHE
, O
impairment B-PHE
of I-PHE
hearing I-PHE
and O
looseness B-PHE
of I-PHE
teeth I-PHE
, O
traumatic B-PHE
injury I-PHE
, O
bone B-PHE
fracture I-PHE
, O
external O
use O
for O
alopecia B-PHE
areata I-PHE
, O
vitiligo B-PHE
. O

-DOCSTART- O


major O
red O
and O
white O
dysentery B-PHE

-DOCSTART- O


1 O
Hypotensive B-PHE
2 O
Promoting O
phagocytosis B-PHE
of I-PHE
mononuclear I-PHE
phagocytes I-PHE
. O

Sedative O
and O
diuretic O
. O

-DOCSTART- O


To O
remove O
heat B-PHE
from I-PHE
the I-PHE
lung I-PHE
, O
relieve O
cough B-PHE
and O
resolve O
phlegm B-PHE
. O

-DOCSTART- O


1)a O
disease O
due O
to O
reducing O
wind B-PHE
pathogen O
of O
the O
heart B-PHE
2) O
mental B-PHE
problem I-PHE
due O
to O
disorder O
of O
opening O
the O
heart O
by O
phlegm B-PHE
. O

-DOCSTART- O


upper O
diabetes B-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
colorectal B-PHE
cancer I-PHE
. O

-DOCSTART- O


linear O
lump B-PHE
of I-PHE
scrofula I-PHE

-DOCSTART- O


settle O
the O
pain B-PHE
and O
tranquilize O

-DOCSTART- O


Enteritis B-PHE
, O
dysentery B-PHE
, O
prolapse B-PHE
of O
rectum O
, O
emission O
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Zidovudine O
inhibits O
the O
activity B-PHE
of I-PHE
HIV-1 I-PHE
reverse I-PHE
transcriptase I-PHE
( O
RT O
) O
via O
DNA B-PHE
chain I-PHE
termination I-PHE
after O
incorporation O
of O
the O
nucleotide B-PHE
analogue I-PHE
. O

-DOCSTART- O


Saireito O
(a O
Chinese O
herbal O
drug O
) O
decreases O
inhibitory O
effect O
of O
prednisolone O
and O
accelerates O
the O
recovery O
of O
rat O
hypothalamic-pituitary-adrenal O
axis O
. O

-DOCSTART- O


Tropicamide O
acts O
by O
blocking O
the O
responses O
of O
the O
iris B-PHE
sphincter I-PHE
muscle I-PHE
to O
the O
iris B-PHE
and I-PHE
ciliary I-PHE
muscles I-PHE
to O
cholinergic B-PHE
stimulation I-PHE
, O
producing O
dilation B-PHE
of O
the O
pupil O
and O
paralysis B-PHE
of O
the O
ciliary O
muscle O
. O

Hydroxyamphetamine O
is O
a O
sympathomimetic O
drug O
, O
that O
is O
, O
a O
drug O
that O
stimulates O
the O
sympathetic B-PHE
nervous I-PHE
system I-PHE
as O
an O
agonist O
of O
human O
TAAR1 O
. O

-DOCSTART- O


Cetuximab O
competitively O
inhibits O
epidermal O
growth O
factor O
and O
TGF B-PHE
alpha I-PHE
, O
thereby O
reducing O
their O
effects O
on O
cell B-PHE
growth I-PHE
and O
metastatic B-PHE
spread I-PHE
. O

Fluorouracil O
metabolites O
incorporate O
into O
both O
RNA B-PHE
and O
DNA B-PHE
; O
inhibits O
synthesis B-PHE
of I-PHE
DNA I-PHE
, O
incorporation O
into O
RNA B-PHE
results O
in O
major O
effects O
on O
both O
RNA B-PHE
processing O
and O
functions O
. O

Carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA B-PHE
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
DNA B-PHE
cross-links O
, O
as O
well O
as O
DNA-protein B-PHE
cross-links O
. O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Maturation B-PHE

-DOCSTART- O


swelling B-PHE
of O
the O
lips O
; O
swollen B-PHE
lips I-PHE

-DOCSTART- O


Breech B-PHE
Presentation I-PHE
in O
Pregnancy O

-DOCSTART- O


HIV B-PHE
Infection I-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
health I-PHE
, O
DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
Memory B-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


dyspnea B-PHE
due O
to O
the O
kidney B-PHE
deficiency I-PHE

-DOCSTART- O


Reproductive B-PHE
systems I-PHE
, O
Mood O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Memory B-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Quality O
of O
life O
, O
UV B-PHE
protection I-PHE
, O
Others O
, O
Man O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Motivation O
, O
Strength B-PHE
and O
power B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
, O
Hemostatic B-PHE
function I-PHE
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Intelligence B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Overall O
CVD B-PHE
, O
dermatological B-PHE
systems I-PHE
health I-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


1.To O
promote O
blood B-PHE
circulation I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
, O
expel O
wind B-PHE
and O
alleviate O
pain B-PHE
. O

2 O
. O
To O
relieve O
asthma B-PHE
. O

-DOCSTART- O


Pulmonary B-PHE
Disease I-PHE
, I-PHE
Chronic I-PHE
Obstructive I-PHE

-DOCSTART- O


Diminshing O
the O
toxicity B-PHE
of I-PHE
kanamycin I-PHE
to O
guinea-pig's O
cochlea B-PHE
. O

the O
levels O
of O
serum B-PHE
cholesterol I-PHE
and O
triglyceride B-PHE
. O

Hindering O
the O
formation O
of O
arteriosclerotic B-PHE
deposits O
in O
the O
vessels O
. O

-DOCSTART- O


protracted O
diarrhea B-PHE
; O
chronic B-PHE
diarrhea I-PHE
; O
prolonged O
diarrhea B-PHE

-DOCSTART- O


Tourette B-PHE
Disorder I-PHE

-DOCSTART- O


Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

Prazosin O
acts O
by O
inhibiting O
the O
postsynaptic O
alpha(1)-adrenoceptors O
on O
vascular B-PHE
smooth I-PHE
muscle I-PHE
. O

This O
inhibits O
the O
vasoconstrictor B-PHE
effect I-PHE
of O
circulating O
and O
locally O
released O
catecholamines B-PHE
, O
resulting O
in O
peripheral B-PHE
vasodilation I-PHE
. O

Oxymetazoline O
is O
a O
direct O
acting O
sympathomimetic O
amine O
, O
which O
acts O
on O
alpha-adrenergic O
receptors O
in O
the O
arterioles O
of O
the O
conjunctiva O
and O
nasal O
mucosa O
. O

-DOCSTART- O


Cyclosporine O
binds O
to O
cyclophilin O
which O
inhibits O
lymphokine B-PHE
production I-PHE
and O
interleukin B-PHE
release I-PHE
, O
shows O
potent O
immunosuppressant O
medication O
. O

-DOCSTART- O


Repeated O
administration O
of O
Yokukansan O
inhibits O
DOI B-PHE
- I-PHE
induced I-PHE
head I-PHE
- I-PHE
twitch I-PHE
response I-PHE
and O
decreases O
expression O
of O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
HT O
) O
2A O
receptors O
in O
the O
prefrontal O
cortex O
. O

-DOCSTART- O


abdominal B-PHE
pain I-PHE
and O
tenesmus B-PHE

-DOCSTART- O


stroke B-PHE
; O
sudden B-PHE
wind-stroke I-PHE
a O
sudden O
and O
severe O
attack O
, O
as O
of O
apoplexy B-PHE

-DOCSTART- O


Glucagon O
binds O
the O
glucagon O
receptor O
, O
a O
G O
protein-coupled O
receptor O
located O
in O
the O
plasma B-PHE
membrane I-PHE
, O
which O
then O
initiates O
a O
dual O
signaling O
pathway O
using O
both O
adenylate O
cyclase O
activation O
and O
increased O
intracellular B-PHE
calcium I-PHE
. O

Adenylate O
cyclase O
manufactures O
cAMP O
( O
cyclic O
AMP O
) O
, O
which O
activates O
protein B-PHE
kinase I-PHE
A I-PHE
( O
cAMP-dependent B-PHE
protein I-PHE
kinase I-PHE
) O
. O

This O
enzyme B-PHE
, O
in O
turn O
, O
activates O
phosphorylase B-PHE
kinase I-PHE
, O
which O
, O
in O
turn O
, O
phosphorylates O
glycogen B-PHE
phosphorylase I-PHE
, O
converting O
into O
the O
active O
form O
called O
phosphorylase B-PHE
A I-PHE

Phosphorylase O
A O
is O
the O
enzyme O
responsible O
for O
the O
release O
of O
glucose-1-phosphate O
from O
glycogen O
polymers O
. O

This O
yields O
glucose O
molecules O
to O
be O
released O
into O
the O
blood O
. O

Glucagon O
receptors O
are O
found O
in O
the O
liver B-PHE
, O
kidney B-PHE
, O
brain B-PHE
and O
pancreatic B-PHE
islet I-PHE
cells I-PHE
. O

The O
glucagon O
mediated O
signals O
lead O
to O
an O
increase O
in O
insulin B-PHE
excretion I-PHE

-DOCSTART- O


Acute B-PHE
Myelogenous I-PHE
Leukemia I-PHE

-DOCSTART- O


miasma O
1 O
pestilential B-PHE
pathogene I-PHE
2 O
malaria B-PHE

-DOCSTART- O


disliking O
wind B-PHE
syndrome I-PHE
due O
to O
external B-PHE
and I-PHE
internal I-PHE
injury I-PHE
. O

-DOCSTART- O


Therapeutic O
effects O
of O
Saireito O
( O
chai-ling-tang O
) O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
on O
lymphedema B-PHE
caused O
by O
radiotherapy O
: O
a O
case O
series O
study O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
kill O
worms B-PHE
and O
relieve O
itch B-PHE
, O
resolve B-PHE
toxin I-PHE
and O
close O
sores B-PHE
. O

-DOCSTART- O


restore O
depression B-PHE
and O
dissipate O
bind O

-DOCSTART- O


dispel O
the O
effects O
of O
alcohol O

-DOCSTART- O


Symptoms O
associated O
with O
stagnation O
of O
liver O
qi O
, O
stagnated O
qi O
truned O
into O
fire O
, O
insufficient O
yin O
blood O

-DOCSTART- O


Allosteric O
interactions O
between O
central O
benzodiazepine O
receptors O
and O
gamma-aminobutyric O
acid O
( O
GABA O
) O
receptors O
potentiate O
the O
effects O
of O
GABA O
. O

-DOCSTART- O


OBJECTIVE O
: O
The O
aim O
of O
this O
study O
was O
to O
analyse O
the O
value O
of O
intraoperative O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
( O
SBB O
) O
. O

So O
far O
, O
only O
a O
few O
studies O
have O
reported O
about O
the O
usefulness O
of O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
. O

METHODS O
: O
Between O
1998 O
and O
2003 O
, O
155 O
SBBs O
were O
performed O
in O
153 O
patients O
with O
micro-Doppler O
( O
81 O
males O
, O
72 O
females O
, O
mean O
age O
: O
59 O
years O
) O
. O

All O
operations O
were O
performed O
using O
a O
ZD-frame O
and O
a O
multiplanar O
computer O
tomography-guided O
trajectory O
planning O
system O
( O
Leibinger O
SPP O
) O
. O

A O
16 O
MHz O
micro-Doppler O
probe O
( O
diameter O
1 O
mm O
, O
DWL O
) O
was O
used O
in O
all O
cases O
to O
explore O
the O
area O
of O
biopsy O
before O
the O
tissue O
probes O
were O
taken O
. O

Serial O
biopsies O
( O
mean O
, O
6 O
samples O
) O
were O
taken O
with O
the O
Sedan O
side-cutting O
cannula O
(n O
= O
145 O
) O
or O
the O
small O
forceps O
(n O
= O
10 O
) O
. O

We O
evaluated O
the O
number O
of O
intraoperative O
detectable O
vessel O
signals O
by O
micro-Doppler O
, O
intraoperative O
bleedings B-PHE
as O
well O
as O
bleedings B-PHE
detected O
by O
postoperative O
CT O
( O
which O
was O
performed O
in O
all O
cases O
) O
. O

We O
compared O
our O
results O
according O
to O
bleeding B-PHE
- O
related O
complications O
with O
the O
data O
of O
stereotactic O
biopsy O
series O
from O
the O
recent O
literature O
. O

RESULTS O
: O
A O
conclusive O
histopathological O
diagnosis O
was O
achieved O
in O
150/153 O
patients O
( O
98 O
% O
) O
. O

A O
re-biopsy O
had O
to O
be O
undertaken O
in O
2 O
cases O
. O

In O
98 O
biopsies O
( O
63 O
% O
) O
, O
no O
vessel O
could O
be O
detected O
with O
the O
micro-Doppler O
. O

In O
the O
remainder O
, O
a O
signal O
of O
arterial B-PHE
vessels I-PHE
was O
detected O
in O
22 O
( O
14 O
%) O
and O
a O
signal O
of O
venous B-PHE
vessels I-PHE
in O
35 O
cases O
( O
23 O
% O
) O
. O

Detection O
of O
a O
vessel B-PHE
in O
the O
micro-Doppler O
led O
to O
a O
change O
of O
the O
biopsy O
site O
in O
each O
case O
within O
the O
same O
trajectory O
. O

Biopsy-related O
bleedings B-PHE
were O
detected O
in O
4 O
cases O
( O
2.6 O
% O
) O
. O

Among O
these O
, O
the O
only O
bleeding B-PHE
which O
occurred O
without O
any O
signs O
of O
vessels B-PHE
in O
the O
micro-Doppler O
happened O
in O
a O
case O
of O
a O
melanoma B-PHE
. O

The O
overall O
biopsy-related O
permanent O
morbidity O
was O
0.6 O
% O
(n O
= O
1 O
) O
. O

The O
biopsy-related O
mortality O
was O
0 O

CONCLUSIONS O
: O
Despite O
the O
overall O
high O
security O
of O
SBB O
, O
the O
use O
of O
intraoperative O
micro-Doppler O
may O
lead O
to O
an O
additional O
reduction O
of O
the O
risk O
for O
a O
biopsy-related O
bleeding B-PHE
without O
enormous O
expense O
. O

-DOCSTART- O


cold O
dysentery B-PHE

-DOCSTART- O


Antiviral O
Treatment O
of O
Chronic B-PHE
Hepatitis I-PHE
B I-PHE

-DOCSTART- O


dispel O
cold B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


For O
the O
prophylaxis O
of O
organ B-PHE
rejection I-PHE
in O
patients O
receiving O
renal O
transplants O
. O

-DOCSTART- O


Purging B-PHE
by O
moisterizing O

-DOCSTART- O


Zidovudine O
inhibits O
the O
activity B-PHE
of I-PHE
HIV-1 I-PHE
reverse I-PHE
transcriptase I-PHE
( O
RT B-PHE
) O
via O
DNA B-PHE
chain I-PHE
termination I-PHE
after O
incorporation O
of O
the O
nucleotide O
analogue O
. O

Efavirenz O
inhibits O
the O
activity B-PHE
of I-PHE
viral I-PHE
RNA-directed I-PHE
DNA I-PHE
polymerase I-PHE
. O

Lamivudine O
is O
a O
synthetic O
nucleoside O
analogue O
and O
this O
nucleoside O
analogue O
is O
incorporated O
into O
viral O
DNA O
by O
HIV B-PHE
reverse I-PHE
transcriptase I-PHE
and O
HBV B-PHE
polymerase I-PHE
, O
resulting O
in O
DNA B-PHE
chain I-PHE
termination I-PHE
. O

-DOCSTART- O


10-Gingerol O
, O
a O
component O
of O
Rikkunshito O
, O
improves O
cisplatin-induced B-PHE
anorexia I-PHE
by O
inhibiting O
acylated B-PHE
ghrelin I-PHE
degradation I-PHE
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
t(8;21)(q22;q22 O
) O
; O
RUNX1-RUNX1T1 O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Monoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Intraocular B-PHE
Melanoma I-PHE

-DOCSTART- O


Hepatitis B-PHE
B I-PHE
Reactivation I-PHE

-DOCSTART- O


Sudden O
stroke O
and O
fulminant O
reversal O
, O
pain B-PHE
in O
heart O
and O
abdomen B-PHE
, O
postpartum O
blood B-PHE
dizziness I-PHE
, O
child O
fright B-PHE
epilepsy I-PHE
, O
wind B-PHE
impediment O
and O
lumbago B-PHE
. O

-DOCSTART- O


Rhizoma O
Coptidis O
( O
processed O
with O
ginger O
) O
Stuffiness B-PHE
and O
fullness B-PHE
sensation O
in O
the O
abdomen O
with O
nausea B-PHE
and O
vomiting B-PHE
caused O
by O
damp-heat B-PHE
in O
combination O
with O
cold B-PHE
. O

-DOCSTART- O


Gallbladder B-PHE
Neoplasms I-PHE

-DOCSTART- O


Urinary B-PHE
tract I-PHE
stone I-PHE
marked O
by O
paroxysmal B-PHE
lumbago I-PHE
or O
pain B-PHE
in O
one O
side O
of O
the O
abdomen O
often O
radiating O
to O
pudendum O
, O
or O
accompanied O
by O
fever B-PHE
, O
hematuria B-PHE
, O
urodynia B-PHE
, O
dysuria B-PHE
, O
discontinuance B-PHE
of O
urination O
, O
yellow B-PHE
fur I-PHE
of I-PHE
the I-PHE
tongue I-PHE
and O
taut B-PHE
pulse I-PHE
. O

-DOCSTART- O


Food O
accumulation O
, O
stomachache B-PHE
, O
abdomin B-PHE
al I-PHE
pain I-PHE
. O

-DOCSTART- O


break O
blood B-PHE

-DOCSTART- O


The O
itching B-PHE
sensation I-PHE
due O
to O
eczema B-PHE

-DOCSTART- O


( O
1) O
wind-warm B-PHE
; O
wind-warm B-PHE
pathogen I-PHE
( O
1 O
) O
wind B-PHE
and O
warm O
blended O
as O
a O
pathogenic O
factor O
. O

( O
2 O
) O
wind-warm B-PHE
syndrome I-PHE
acute O
febrile B-PHE
diseases I-PHE
caused O
by O
wind-warm B-PHE
pathogene I-PHE
occurring O
in O
winter O
and O
spring O
, O
characterized O
by O
chills B-PHE
and O
fever B-PHE
, O
thirst B-PHE
sweating I-PHE
, O
cough B-PHE
and O
headache B-PHE
in O
the O
initial O
stage O
, O
and O
then O
, O
delirium B-PHE
and O
maculation B-PHE
in O
the O
following O
stage O
. O

-DOCSTART- O


fever B-PHE
and O
aversion O
to O
cold B-PHE

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE

-DOCSTART- O


pyogenic B-PHE
infections I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
the O
signs O
and O
symptoms O
of O
idiopathic O
Parkinson's B-PHE
disease I-PHE
. O

Also O
used O
for O
the O
treatment O
of O
restless B-PHE
legs I-PHE
syndrome I-PHE
. O

-DOCSTART- O


soothe O
the O
sinews B-PHE
and O
the O
network B-PHE
vessels I-PHE

-DOCSTART- O


acute B-PHE
arthritis I-PHE
; O
gout B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Quality O
of O
life O
, O
absorption O
, O
Liver B-PHE
health I-PHE
, O
motility O
, O
Liver B-PHE
, O
Others O

-DOCSTART- O


Methyclothiazide O
appears O
to O
block O
the O
active O
reabsorption B-PHE
of I-PHE
chloride I-PHE
and O
possibly O
sodium O
in O
the O
ascending O
loop O
of O
Henle O
, O
altering O
electrolyte O
transfer O
in O
the O
proximal O
tubule O
. O

Pargyline O
is O
a O
monoamine O
oxidase O
B O
( O
MAO-B O
) O
inhibitor O
with O
antihypertensive O
properties O
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Quality O
of O
life O
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
General O
woman O
, O
Inflammation B-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


Grepafloxacin O
exerts O
its O
antibacterial B-PHE
activity I-PHE
by O
inhibiting O
bacterial B-PHE
topoisomerase I-PHE
II I-PHE
( O
DNA B-PHE
gyrase I-PHE
) O
and O
topoisomerase B-PHE
IV I-PHE
, O
essential O
enzymes O
for O
duplication O
, O
transcription O
, O
and O
repair O
of O
bacterial B-PHE
DNA I-PHE
. O

-DOCSTART- O


Other O
system B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


To O
remove O
heat B-PHE
and O
counteract O
toxicity B-PHE
, O
to O
expel O
intestinal B-PHE
worms I-PHE
, O
stanch O
bleeding B-PHE
. O

-DOCSTART- O


Beta-Thalassemia B-PHE

-DOCSTART- O


constipation B-PHE

-DOCSTART- O


Methotrexate O
anti-tumor O
activity O
is O
a O
result O
of O
the O
inhibition O
of O
folic B-PHE
acid I-PHE
reductase I-PHE
, O
leading O
to O
inhibition O
of O
DNA B-PHE
synthesis I-PHE
and O
inhibition O
of O
cellular B-PHE
replication I-PHE
. O

Golimumab O
inhibits O
the O
activity B-PHE
of I-PHE
the I-PHE
cytokine I-PHE
, O
tumor B-PHE
necrosis I-PHE
factor I-PHE
alpha I-PHE
. O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Lipid O
profile O

-DOCSTART- O


Untreated O
Childhood B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


The O
precise O
mechanism O
of O
action O
has O
not O
been O
fully O
determined O
, O
but O
the O
main O
mechanism O
of O
fluorouracil O
is O
thought O
to O
be O
the O
binding O
of O
the O
deoxyribonucleotide O
of O
the O
drug O
( O
FdUMP O
) O
and O
the O
folate O
cofactor O
, O
N50-methylenetetrahydrofolate O
, O
to O
thymidylate O
synthase O
( O
TS O
) O
to O
form O
a O
covalently O
bound O
ternary O
complex O
. O

This O
results O
in O
the O
inhibition O
of O
the O
formation B-PHE
of I-PHE
thymidylate I-PHE
from O
uracil O
, O
which O
leads O
to O
the O
inhibition O
of O
DNA B-PHE
and I-PHE
RNA I-PHE
synthesis I-PHE
and O
cell B-PHE
death I-PHE
. O

Fluorouracil O
can O
also O
be O
incorporated O
into O
RNA B-PHE
in O
place O
of O
uridine O
triphosphate O
( O
UTP O
) O
, O
producing O
a O
fraudulent B-PHE
RNA I-PHE
and O
interfering O
with O
RNA B-PHE
processing I-PHE
and O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


yellow B-PHE
or I-PHE
reddish I-PHE
urine I-PHE
; O
dark B-PHE
urine I-PHE

-DOCSTART- O


Postpartum B-PHE
bleeding I-PHE
, O
migraine B-PHE
. O

-DOCSTART- O


penis B-PHE
ulceration I-PHE

-DOCSTART- O


Cardiac B-PHE
carbuncle I-PHE
has O
half O
conscious O
, O
stuffiness B-PHE
in O
the O
heart O
, O
and O
forgetting O
well O
when O
something O
occurred O
. O

-DOCSTART- O


Adult B-PHE
Pure I-PHE
Erythroid I-PHE
Leukemia I-PHE

-DOCSTART- O


Quality O
of O
life O

-DOCSTART- O


phlegmy B-PHE
fire O
a O
morbid O
condition O
produced O
by O
long-standing O
depression B-PHE
of O
Gi O
which O
turns O
into O
fire O
and O
changes O
the O
body O
fluid O
into O
phlegm B-PHE
, O
usually O
causing B-PHE
mental I-PHE
disturbances O
such O
as O
hysteria B-PHE
, O
mania B-PHE
. O

-DOCSTART- O


AIM O
: O
Zhi O
Zhu O
Wan O
( O
ZZW O
) O
is O
a O
classical O
Chinese O
medical O
formulation O
used O
for O
the O
treatment O
of O
functional O
dyspepsia B-PHE
that O
attributed O
to O
Spleen B-PHE
- I-PHE
deficiency I-PHE
Syndrome I-PHE
. O

ZZW O
contains O
Atractylodes O
Rhizome O
and O
Fructus O
Citrus O
Immaturus O
, O
the O
later O
originates O
from O
both O
Citrus O
aurantium O
L. O
( O
BZZW O
) O
and O
Citrus O
sinensis O
Osbeck O
( O
RZZW O
) O
. O

The O
present O
study O
is O
designed O
to O
elucidate O
disparities O
in O
the O
clinical O
efficacy O
of O
two O
ZZW O
varieties O
based O
on O
the O
pharmacokinetics O
of O
naringenin O
and O
hesperetin O
. O

MEHTOD O
: O
After O
oral O
administration O
of O
ZZWs O
, O
blood O
sample O
was O
collected O
from O
healthy O
volunteers O
at O
designed O
time O
points O
. O

Naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
by O
RP-HPLC O
, O
pharmacokinetic O
parameters O
were O
processed O
using O
mode-independent O
methods O
with O
WINNONLIN O
. O

RESULTS O
: O
After O
oral O
administration O
of O
BZZW O
, O
both O
naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
, O
and O
demonstrated O
similar O
pharmacokinetic O
parameters O
. O

Ka O
was O
0.384+/-0.165 O
and O
0.401+/-0.159 O
, O
T(1/2(ke))(h O
) O
was O
5.491+/-3.926 O
and O
5.824+/-3.067 O
, O
the O
AUC O
( O
mg/Lh O
) O
was O
34.886+/-22.199 O
and O
39.407+/-19.535 O
for O
naringenin O
and O
hesperetin O
, O
respectively O
. O

However O
, O
in O
the O
case O
of O
RZZW O
, O
only O
hesperetin O
was O
found O
in O
plasma O
, O
but O
the O
pharmacokinetic O
properties O
for O
hesperetin O
in O
RZZW O
was O
different O
from O
that O
in O
BZZW O
. O

T(max O
) O
for O
hesperetin O
in O
RZZW O
is O
about O
8.515h O
, O
and O
its O
C(max O
) O
is O
much O
larger O
than O
that O
of O
BZZW O
. O

Moreover O
, O
it O
was O
eliminated O
slowly O
as O
it O
possessed O
a O
much O
larger O
AUC O
value O
. O

CONCLUSION O
: O
The O
distinct O
therapeutic O
orientations O
of O
the O
Chinese O
medical O
formula O
ZZWs O
with O
different O
Fructus O
Citrus O
Immaturus O
could O
be O
elucidated O
based O
on O
the O
pharmacokinetic O
parameters O
of O
constituents O
after O
oral O
administration O
. O

-DOCSTART- O


Eye B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
Eye B-PHE
health I-PHE
, O
Eye B-PHE
health I-PHE
, O
Others O
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Strength O
and O
power O
, O
Intelligence B-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


dizziness B-PHE
and O
palpitation B-PHE
due O
to O
congested B-PHE
fluids I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Fat B-PHE
storage I-PHE
and O
oxidation O

-DOCSTART- O


inner O
impairment B-PHE

-DOCSTART- O


Reproductive B-PHE
systems I-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Menopausal B-PHE
woman I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Metabolism B-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Woman O
, O
Quality O
of O
life O
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Liver B-PHE
, O
Others O
, O
Kids O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Liver B-PHE
health I-PHE
, O
Strength B-PHE
and O
power B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Intelligence B-PHE
, O
Overall O
CVD B-PHE
, O
General O
woman O
, O
Body B-PHE
weight I-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


tonify O
the O
kidney B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Inflammation B-PHE
, O
Other O
system O
health O
, O
Others O

-DOCSTART- O


The O
anti-inflammatory B-PHE
effects I-PHE
of O
diclofenac O
are O
believed O
to O
be O
due O
to O
inhibition O
of O
both O
leukocyte B-PHE
migration I-PHE
and O
the O
enzyme B-PHE
cylooxygenase I-PHE
( O
COX-1 B-PHE
and O
COX-2 B-PHE
) O
, O
leading O
to O
the O
peripheral O
inhibition O
of O
prostaglandin B-PHE
synthesis I-PHE
. O

-DOCSTART- O


To O
promote O
blood B-PHE
circulation I-PHE
, O
strengthen O
the O
muscles B-PHE
and O
tendon B-PHE
, O
regulate O
the O
function O
between O
qi O
and O
blood O
. O

-DOCSTART- O


promote O
blood B-PHE
vessel I-PHE

-DOCSTART- O


For O
appendicitis B-PHE
, O
used O
together O
with O
same O
dose O
of O
pills O
of O
Radix O
et O
Rhizoma O
Rhei O
and O
Rhizoma O
Coptidis O
, O
or O
mixed O
with O
same O
dose O
of O
Cinnabaris O
, O
applying O
on O
point O
Lanwei O
( O
Extra33 O
) O
. O

-DOCSTART- O


Heavy B-PHE
flow I-PHE
in I-PHE
period I-PHE
due O
to O
blood B-PHE
stagnation I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
liver B-PHE
cancer I-PHE
. O

-DOCSTART- O


Hyperactivity B-PHE
of O
the O
liver-yang O
, O
hypertension B-PHE
, O
dizziness B-PHE
, O
vertigo B-PHE
, O
insomnia B-PHE
, O
amnesia B-PHE
. O

-DOCSTART- O


moisten B-PHE
face I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Mood O
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Intelligence B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Inflammation B-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


diarrhea B-PHE
due O
to O
dysfunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE

-DOCSTART- O


harmonize O
the O
stomach B-PHE

-DOCSTART- O


To O
warm O
the O
kidney B-PHE
, O
invigorate O
yang O
, O
replenish O
the O
vital B-PHE
essence I-PHE
and O
reinforce O
the O
marrow B-PHE

-DOCSTART- O


To O
benefit O
qi O
and O
revitalize O
blood B-PHE
; O
To O
nourish O
yin O
and O
tonify O
yang O

-DOCSTART- O


For O
the O
treatment O
of O
essential B-PHE
hypertension I-PHE
, O
alone O
or O
as O
an O
adjunct O
. O

Also O
for O
the O
management O
of O
severe B-PHE
hypertension I-PHE
when O
the O
drug O
cannot O
be O
given O
orally O
or O
when O
blood B-PHE
pressure I-PHE
must O
be O
lowered O
immediately O
, O
congestive B-PHE
heart I-PHE
failure I-PHE
( O
in O
combination O
with O
cardiac O
glycosides O
and O
diuretics O
and O
/ O
or O
with O
isosorbide O
dinitrate O
) O
, O
and O
hypertension B-PHE
secondary I-PHE
to O
pre-eclampsia B-PHE
/ O
eclampsia B-PHE
. O

-DOCSTART- O


the O
stagnation B-PHE
of O
Gi O
a O
morbid B-PHE
condition I-PHE
due O
to O
impeded B-PHE
circulation I-PHE
of O
Gi O
that O
leads O
to O
a O
local B-PHE
obstruction I-PHE
, O
manifested O
by O
distension B-PHE
or O
pain B-PHE
in O
the O
affected O
part O
. O

-DOCSTART- O


facial B-PHE
hemiparalysis I-PHE
due O
to O
wind B-PHE
stroke I-PHE

-DOCSTART- O


The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin O
and O
other O
activated O
clotting O
factors O
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization O
of O
fibrinogen O
to O
fibrin O
and O
the O
subsequent O
formation B-PHE
of I-PHE
clots I-PHE
. O

-DOCSTART- O


This O
is O
a O
syndrome O
that O
the O
both O
cheeks O
of O
children O
turn O
red O
. O

-DOCSTART- O


exogenous B-PHE
febrile I-PHE
disease I-PHE
of O
four O
seasons O

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
dispel O
stasis B-PHE
, O
regulate O
menstruation B-PHE
and O
relieve O
pain B-PHE
, O
nourish O
blood B-PHE
and O
quiet O
spirit O
, O
cool O
blood B-PHE
and O
disperse O
welling O
abscess B-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
to O
counteract O
toxicity B-PHE
, O
to O
kill O
parasites B-PHE
, O
and O
to O
relieve O
itching B-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Quality O
of O
life O
, O
Inflammation B-PHE
, O
Protective O
immunity B-PHE
, O
Others O

-DOCSTART- O


invigorate O
the O
spleen B-PHE

-DOCSTART- O


Alzheimer's B-PHE
Disease I-PHE

-DOCSTART- O


Quality O
of O
life O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Mood O

-DOCSTART- O


spitting O
bloody B-PHE
pus I-PHE
; O

cough B-PHE
with O
bloody B-PHE
pus I-PHE

-DOCSTART- O


stop O
dysentery B-PHE

-DOCSTART- O


palpitation B-PHE

-DOCSTART- O


Hochuekkito O
, O
a O
Kampo O
( O
Traditional O
Japanese O
Herbal O
) O
Medicine O
, O
and O
its O
Polysaccharide O
Portion O
Stimulate O
G B-PHE
- I-PHE
CSF I-PHE
Secretion I-PHE
from O
Intestinal O
Epithelial O
Cells O
. O

-DOCSTART- O


stranguria B-PHE
due O
to O
heat B-PHE
; O
heat-type B-PHE
stranguria I-PHE

-DOCSTART- O


old O
ulceration B-PHE

-DOCSTART- O


1 O
To O
relieve O
carbuncle B-PHE
and O
drain B-PHE
pus I-PHE
. O

For O
the O
early O
stage O
of O
carbuncle B-PHE
or O
carbuncle B-PHE
with O
unruptured O
abscess B-PHE
. O

2 O
To O
expel O
wind B-PHE
and O
kill O
parasites B-PHE
. O

For O
tinea B-PHE
infection I-PHE
and O
leprosy B-PHE
. O

-DOCSTART- O


For O
tonifying O
blood B-PHE

-DOCSTART- O


Anti-inflammatory B-PHE
activity I-PHE
of O
Gumiganghwaltang O
through O
the O
inhibition O
of O
nuclear B-PHE
factor-kappa I-PHE
B I-PHE
activation I-PHE
in O
peritoneal O
macrophages O
. O

-DOCSTART- O


pain B-PHE
from I-PHE
cramped I-PHE
tendons I-PHE
and I-PHE
bones I-PHE

-DOCSTART- O


a O
stomachache B-PHE
due O
to O
exhaustion O
of O
vital O
energy O

-DOCSTART- O


deficiency O
of O
the O
Yang O
of O
the O
spleen B-PHE
and O
the O
kidney B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
remove O
toxic B-PHE
materials I-PHE
; O
To O
tonify O
kidney B-PHE
and O
revitalize O
blood B-PHE

-DOCSTART- O


Blood B-PHE
activation I-PHE
and O
injury B-PHE
healing I-PHE

-DOCSTART- O


hemicrania B-PHE
; O
migraine B-PHE
; O
megrim B-PHE

-DOCSTART- O


1 O
For O
cases O
of O
menorrhagia B-PHE
accompanied O
with O
listlessness B-PHE
and O
pale B-PHE
complexion I-PHE
due O
to O
deficiency B-PHE
of I-PHE
vital I-PHE
energy I-PHE
Radix O
Ginseng O
Jilin O
to O
invigorate O
vital B-PHE
energy I-PHE
and O
control O
blood B-PHE
of O
profuse O
uterine B-PHE
bleeding I-PHE
leading O
to O
deadly O
coldness B-PHE
of I-PHE
limbs I-PHE
and O

-DOCSTART- O


Fructus O
Crataegi O
( O
charred O
) O
: O
Has O
more O
digestant O
action O
and O
is O
particularly O
useful O
for O
stagnation B-PHE
of I-PHE
undigested I-PHE
meat I-PHE
and O
diarrhea B-PHE
with O
inadequate B-PHE
discharge I-PHE
from I-PHE
the I-PHE
bowels I-PHE
. O

-DOCSTART- O


Woman O
, O
Eldery O
, O
menopausal B-PHE
woman I-PHE
, O
Others O

-DOCSTART- O


Rapamycin O
binds O
to O
the O
immunophilin B-PHE
FK I-PHE
Binding I-PHE
Protein-12 I-PHE
( O
FKBP-12 B-PHE
) O
to O
generate O
an O
immunosuppressive B-PHE
complex I-PHE
that O
binds O
to O
and O
inhibits O
the O
activation B-PHE
of I-PHE
the I-PHE
mammalian I-PHE
Target I-PHE
Of I-PHE
Rapamycin I-PHE
( O
mTOR B-PHE
) O
, O
a O
key O
regulatory O
kinase B-PHE
. O

This O
results O
in O
inhibition O
of O
T B-PHE
lymphocyte I-PHE
activation I-PHE
and I-PHE
proliferation I-PHE
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine B-PHE
( O
IL-2 B-PHE
, O
IL-4 B-PHE
, O
and O
IL-15 B-PHE
) O
stimulation O
and O
inhibition O
of O
antibody B-PHE
production I-PHE
. O

Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-PHE
kinases I-PHE
( O
TK B-PHE
) O
, O
thereby O
inhibiting O
ATP B-PHE
binding I-PHE
and O
preventing O
phosphorylation B-PHE
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-PHE
transduction I-PHE
pathways I-PHE
. O

This O
agent O
inhibits O
TK B-PHE
encoded O
by O
the O
bcr-abl O
oncogene O
as O
well O
as O
receptor O
TKs O
encoded O
by O
the O
c-kit O
and O
platelet-derived O
growth O
factor O
receptor O
( O
PDGFR O
) O
oncogenes O
. O

Biochemical O
analyses O
raise O
the O
possibility O
that O
inhibition O
of O
4E-BP1 B-PHE
phosphorylation I-PHE
may O
be O
particularly O
important O
for O
the O
synergistic O
effects O
of O
PTK O
inhibitor O
/ O
rapamycin O
combinations O
. O

-DOCSTART- O


convulsion B-PHE
; O

epilepsy B-PHE

-DOCSTART- O


general O
edema B-PHE
with O
abdominal B-PHE
distension I-PHE

-DOCSTART- O


nourish O
Gi O
( O
Qi O
) O
and O
blood B-PHE

-DOCSTART- O


Acne B-PHE
Vulgaris I-PHE

-DOCSTART- O


Gramicidin O
D O
binds O
and O
inserts O
itself O
into O
bacterial B-PHE
membranes I-PHE
and O
results O
in O
membrane B-PHE
disruption I-PHE
and O
permeabilization O
, O
which O
leads O
to O
cell B-PHE
death I-PHE
. O

Polymyxin O
B O
sulfate O
interacts O
with O
the O
lipopolysaccharide O
of O
the O
cytoplasmic O
outer O
membrane O
of O
Gram-negative O
bacteria O
, O
altering O
membrane O
permeability O
and O
causing O
cell B-PHE
death I-PHE
. O

Neomycin O
is O
a O
bactericidal O
aminoglycoside O
antibiotic O
that O
binds O
to O
the O
30S O
ribosome O
of O
susceptible O
organisms O
. O

Binding O
interferes O
with O
mRNA B-PHE
binding I-PHE
and O
acceptor B-PHE
tRNA I-PHE
sites I-PHE
and O
results O
in O
the O
production O
of O
non-functional O
or O
toxic B-PHE
peptides I-PHE
. O

-DOCSTART- O


To O
dispel O
phlegm B-PHE
, O
to O
restore O
consciousness B-PHE
, O
and O
to O
reduce O
modulation B-PHE
and O
cause O
the O
subsidence B-PHE
of I-PHE
swelling I-PHE
. O

-DOCSTART- O


To O
warm O
the O
kidney B-PHE
and O
cause O
diuresis B-PHE
. O

-DOCSTART- O


Chronic B-PHE
hepatitis I-PHE

-DOCSTART- O


This O
paper O
was O
designed O
to O
study O
metabonomic O
characters O
of O
the O
hepatotoxicity O
induced O
by O
alcohol O
and O
the O
intervention O
effects O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
classic O
traditional O
Chinese O
medicine O
formula O
for O
treatment O
of O
jaundice B-PHE
and O
liver B-PHE
disorders I-PHE
in O
China O
. O

Urinary O
samples O
from O
control O
, O
alcohol- O
and O
YCHT-treated O
rats O
were O
analyzed O
by O
ultra-performance O
liquid O
chromatography O
/ O
electrospray O
ionization O
quadruple O
time-of-flight O
mass O
spectrometry O
( O
UPLC/ESI-QTOF-MS O
) O
in O
positive O
ionization O
mode O
. O

The O
total O
ion O
chromatograms O
obtained O
from O
the O
control O
, O
alcohol- O
and O
YCHT-treated O
rats O
were O
easily O
distinguishable O
using O
a O
multivariate O
statistical O
analysis O
method O
such O
as O
the O
principal O
components O
analysis O
( O
PCA O
) O
. O

The O
greatest O
difference O
in O
metabolic O
profiling O
was O
observed O
from O
alcohol-treated O
rats O
compared O
with O
the O
control O
and O
YCHT-treated O
rats O
. O

The O
positive O
ions O
m/z O
664.3126 O
( O
9 O
min O
) O
was O
elevated O
in O
urine O
of O
alcohol-treated O
rats O
, O
whereas O
, O
ions O
m/z O
155.3547 O
( O
10.96 O
min O
) O
and O
708.2932 O
( O
9.01 O
min O
) O
were O
at O
a O
lower O
concentration O
compared O
with O
that O
in O
urine O
of O
control O
rats O
, O
however O
, O
these O
ions O
did O
not O
indicate O
a O
statistical O
difference O
between O
control O
rats O
and O
YCHT-treated O
rats O
. O

The O
ion O
m/z O
664.3126 O
was O
found O
to O
correspond O
to O
ceramide O
( O
d18:1/25:0 O
) O
, O
providing O
further O
support O
for O
an O
involvement O
of O
the O
sphingomyelin O
signaling O
pathway O
in O
alcohol B-PHE
hepatotoxicity I-PHE
and O
the O
intervention O
effects O
of O
YCHT O
. O

-DOCSTART- O


abdominal B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
parasitosis I-PHE
; O
abdominal B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
ascariasis I-PHE

-DOCSTART- O


deficiency B-PHE
of I-PHE
the I-PHE
heart I-PHE
; O
deficiency B-PHE
syndrome I-PHE
of I-PHE
the I-PHE
heart I-PHE
including O
deficiency B-PHE
of I-PHE
blood I-PHE
and O
Eum O
, O
and O
insufficiency O
of O
Gi O
and O
Yang O
of O
the O
heart O

-DOCSTART- O


galactostasis B-PHE
; O
hypogalactia B-PHE
; O
scant B-PHE
breast I-PHE
; O
inadequacy B-PHE
of I-PHE
lactation I-PHE

-DOCSTART- O


Pregnancy B-PHE
Outcome O

-DOCSTART- O


disperse O
wart B-PHE

-DOCSTART- O


Follitropin O
alpha O
is O
a O
recombinant O
form O
of O
endogenous O
follicle O
stimulating O
hormone O
( O
FSH O
) O
. O

FSH O
binds O
to O
the O
follicle O
stimulating O
hormone O
receptor O
which O
is O
a O
G-coupled O
transmembrane O
receptor O
. O

Binding O
of O
the O
FSH O
to O
its O
receptor O
seems O
to O
induce O
phosphorylation B-PHE
and O
activation B-PHE
of I-PHE
the I-PHE
PI3K I-PHE
( O
Phosphatidylinositol-3-kinase O
) O
and O
Akt O
signaling O
pathway O
, O
which O
is O
known O
to O
regulate O
many O
other O
metabolic O
and O
related O
survival/maturation O
functions O
in O
cells O
. O

-DOCSTART- O


Vaginitis B-PHE

-DOCSTART- O


Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Mood O

-DOCSTART- O


invigorate O
the O
spleen B-PHE
and O
promote O
the O
stomach B-PHE

-DOCSTART- O


nocturnal B-PHE
enuresis I-PHE
and O
frequency B-PHE
of I-PHE
micturition I-PHE

-DOCSTART- O


jaundice B-PHE
related O
to O
immoderate O
drinking O
; O
alcoholic B-PHE
jaundice I-PHE
one O
of O
the O
five O
types O
of O
jaundice B-PHE
. O

jaundice B-PHE
caused O
by O
endogenous O
damp-heat B-PHE
due O
to O
indulging O
in O
alcohol O
, O
manifested O
as O
yellowish B-PHE
pigmentation I-PHE
of I-PHE
the I-PHE
skin I-PHE
and I-PHE
sclera I-PHE
, O
chest B-PHE
distress I-PHE
, O
anorexia B-PHE
, O
nausea B-PHE
and O
vomiting B-PHE

-DOCSTART- O


Treatment O
of O
fever B-PHE
with O
constipation B-PHE
, O
retention O
of O
the O
feces O
and O
abdominal B-PHE
pain I-PHE
, O
dysentery B-PHE
with O
inadequate O
discharge O
from O
the O
bowels B-PHE
, O
jaundice B-PHE
caused O
by O
damp-heat B-PHE
, O
haematemesis B-PHE
, O
epistaxis B-PHE
, O
inflammation B-PHE
of O
eye O
and O
swelling B-PHE
of O
the O
throat O
due O
to O
heat B-PHE
in O
the O
blood O
, O
appendicitis B-PHE
with O
abdominal B-PHE
pain I-PHE
, O
boils B-PHE
, O
sores B-PHE
and O
abscess B-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
traumatic B-PHE
injuries I-PHE
, O
hemorrhage B-PHE
from O
the O
upper B-PHE
gastrointestinal I-PHE
tract I-PHE
. O

External O
use O
for O
scalds B-PHE
and O
burns.Radixet O
Rhizoma O
Rhei O
( O
stir-fried O
with O
wine O
) O
Inflammation B-PHE
of O
the O
eye O
, O
swelling B-PHE
of O
the O
throat O
and O
painful O
swelling B-PHE
of O
the O
gums O
. O

Radix O
et O
Rhizoma O
Rhei O
( O
prepared O
) O
Boils B-PHE
, O
sores B-PHE
and O
abscess B-PHE
. O

Radix O
et O
Rhizoma O
Rhei O
( O
carbonized O
) O
Hemorrhage B-PHE
with O
blood B-PHE
stasis I-PHE
due O
to O
heat B-PHE
in O
the O
blood O
. O

-DOCSTART- O


Diarrhea B-PHE
, O
Malnutrition B-PHE

-DOCSTART- O


Menstrual B-PHE
discomfort I-PHE
, O
feelings O
of O
heat B-PHE
, O
flushed B-PHE
face I-PHE
, O
irritability B-PHE

-DOCSTART- O


Schizophrenia B-PHE

-DOCSTART- O


regurgitation B-PHE
; O
frequent B-PHE
vomiting I-PHE

-DOCSTART- O


For O
promoting O
diuresis B-PHE
and O
desolving O
inflammation B-PHE
. O

-DOCSTART- O


jaundice B-PHE
a O
morbid O
condition O
clinically O
characterized O
by O
yellow-brown B-PHE
pigmentation I-PHE
of I-PHE
the I-PHE
skin I-PHE
and I-PHE
sclera I-PHE
and O
dark B-PHE
yellow I-PHE
colored I-PHE
urine I-PHE
, O
and O
classified O
into O
two O
types O
, O
Yang B-PHE
jaundice I-PHE
and O
Eum B-PHE
jaundice I-PHE
; O

one O
of O
the O
five O
types O
of O
jaundice B-PHE
. O

-DOCSTART- O


Post-operative B-PHE
Pain I-PHE

-DOCSTART- O


Angiotensin B-PHE
II I-PHE
is O
a O
small O
hormone O
in O
the O
body O
and O
part O
of O
the O
RAS B-PHE
. O

-DOCSTART- O


Treatment O
of O
deficiency B-PHE
of I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE
, O
lassitude B-PHE
, O
palpitation B-PHE
, O
arrhythmia B-PHE
. O

-DOCSTART- O


tenesmus B-PHE

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
free O
menstruation B-PHE
( O
raw O
) O
, O
transform O
stasis B-PHE
and O
stanch O
bleeding B-PHE
( O
scorch-fry O
) O
. O

-DOCSTART- O


Bradycardia B-PHE
, O
sick B-PHE
sinus I-PHE
syndrome I-PHE
, O
angina B-PHE
and O
cardiac B-PHE
insufficiency I-PHE
, O
arrhythmia B-PHE
. O

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
pain B-PHE
in O
lumbus O
and O
legs O
, O
numbness B-PHE
of I-PHE
limbs I-PHE
, O
sprain B-PHE
from O
knocks B-PHE
and O
falls B-PHE
, O
sequel O
of O
poliomyelitis B-PHE
. O

-DOCSTART- O


Fenretinide O
treatment O
may O
cause O
ceramide B-PHE
to O
build O
up O
in O
tumor B-PHE
cells I-PHE
and O
is O
associated O
with O
the O
accumulation O
of O
reactive B-PHE
oxygen I-PHE
species I-PHE
, O
resulting O
in O
cell B-PHE
death I-PHE
through O
apoptosis B-PHE
and/or O
necrosis B-PHE
. O

Sodium O
butyrate O
( O
NaB O
) O
, O
a O
short O
chain O
fatty O
acid O
, O
is O
a O
HDAC O
inhibitor O
and O
induces O
growth B-PHE
arrest I-PHE
and O
apoptosis B-PHE
in O
a O
variety O
of O
human O
cancer O
cells O
. O

-DOCSTART- O


Treatment O
of O
rheumatic B-PHE
or I-PHE
rheumatoid I-PHE
arthrits I-PHE
with O
muscular B-PHE
contracture I-PHE
and O
severe O
joint B-PHE
pain I-PHE
, O
fever B-PHE
recurring O
daily O
in O
the O
afternoon O
, O
fever B-PHE
in O
infants O
with O
malnutrition B-PHE
. O

-DOCSTART- O


headache B-PHE
due O
to O
adverse O
rising O
of O
phlegm B-PHE

-DOCSTART- O


To O
relax O
the O
bowels B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


To O
benefit O
vital B-PHE
energy I-PHE
to O
control O
blood B-PHE
. O

-DOCSTART- O


Graft B-PHE
Versus I-PHE
Host I-PHE
Disease I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
, O
and O
to O
remove O
the O
retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
. O

-DOCSTART- O


Rheumatoid B-PHE
Arthritis I-PHE

-DOCSTART- O


Type B-PHE
1 I-PHE
Diabetes I-PHE
Mellitus I-PHE

-DOCSTART- O


This O
is O
carbuncle B-PHE
and O
cellulites B-PHE
occurred I-PHE
on I-PHE
the I-PHE
back I-PHE
. O

-DOCSTART- O


Hypoglycemia B-PHE

-DOCSTART- O


swelling B-PHE
and O
pain B-PHE
of O
the O
anus O

-DOCSTART- O


Neostigmine O
is O
used O
for O
the O
symptomatic O
treatment O
of O
myasthenia B-PHE
gravis I-PHE
by O
improving O
muscle B-PHE
tone I-PHE
. O

-DOCSTART- O


Vaginal B-PHE
discharge I-PHE
, O
strangury B-PHE
syndrome I-PHE
, O
swelling B-PHE
toxin I-PHE
of O
clove B-PHE
sore I-PHE
, O
parotitis B-PHE
, O
mastitis B-PHE
, O
lymphrnoditis B-PHE
. O

-DOCSTART- O


Chunghyuldan O
( O
Daio-Orengedokuto O
in O
Japanese O
) O
( O
CHD O
) O
has O
been O
used O
as O
an O
antihyperlipidemic B-PHE
and O
antiischemic B-PHE
agent I-PHE
in O
Korea O
. O

To O
evaluate O
in O
vitro O
the O
efficacy O
of O
Chunghyuldans O
( O
CHDs O
) O
metabolized O
with O
and O
without O
human B-PHE
intestinal I-PHE
microflora I-PHE
against O
brain B-PHE
ischemia I-PHE
, O
we O
investigated O
its O
anti-inflammatory B-PHE
effect I-PHE
on O
LPS-induced O
RAW264.7 O
cells O
. O

Both O
metabolized O
CHD O
( O
MCHD O
) O
and O
CHD O
showed O
antioxidant B-PHE
activities I-PHE
in O
vitro O
, O
and O
inhibited O
nitric O
oxide O
( O
NO O
) O
and O
prostaglandin B-PHE
E2 I-PHE
( O
PGE2 B-PHE
) O
productions O
in O
lipopolysaccharide O
( O
LPS)-induced O
RAW264.7 O
cells O
. O

These O
also O
inhibited O
enzyme B-PHE
activities I-PHE
and O
protein B-PHE
expressions I-PHE
of O
inducible O
NO B-PHE
synthase I-PHE
and O
cyclooxygenase-2 B-PHE
in O
LPS-induced O
RAW264.7 O
cells O
. O

MCHD-inhibitory O
activity O
against O
NO B-PHE
and I-PHE
PGE2 I-PHE
productions I-PHE
in O
LPS-induced O
RAW264.7 O
cells O
was O
more O
potent O
than O
those O
of O
CHD O
. O

These O
results O
suggest O
that O
CHD O
may O
show O
potent O
anti-inflammatory B-PHE
activity I-PHE
in O
vivo O
and O
can O
improve O
brain B-PHE
ischemia I-PHE
. O

-DOCSTART- O


relieve O
throat B-PHE

-DOCSTART- O


a O
disease O
that O
menstruation B-PHE
is O
not O
even O
due O
to O
coldness B-PHE

-DOCSTART- O


1 O
Sennoside O
A O
is O
the O
component O
for O
purgation O
. O

2 O
. O
Promoting O
biliary B-PHE
secretion I-PHE
and O
enhancing O
the O
amount O
of O
bilirubin B-PHE
and O
bile B-PHE
acid I-PHE
. O

3 O
. O
Rhein O
and O
Emodin O
exert O
bacteriostatic O
effect O
by O
inhibting O
the O
synthesis B-PHE
of I-PHE
DNA I-PHE
, O
RNA O
and O
protein O
in O
bacteria O

4 O
. O
Emodin O
is O
a O
component O
for O
hypotensive B-PHE

5 O
. O
Oral O
use O
of O
its O
extract O
reduces O
the O
raio O
of O
serum B-PHE
cholesterol I-PHE
and O
total O
phospholipid B-PHE
in O
rabbits O
with O
hypercholesterolemia B-PHE
. O

6 O
. O
Chrysophanol O
, O
an O
other O
active O
component O
, O
exerts O
a O
hemostatic B-PHE
effect I-PHE
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
engender O
liquid O
, O
moisten O
dryness B-PHE
and O
harmonize O
center O
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Ulcerative B-PHE
Colitis I-PHE

-DOCSTART- O


1 O
Its O
aqueous O
infusion O
exerts O
a O
significant O
diuretic B-PHE
effect I-PHE
in O
experimental O
animals O
. O

2 O
Shortening O
clotting B-PHE
time O
and O
bleeding B-PHE
time O
, O
and O
decreasing O
the O
permeability O
of O
blood O
vessels O
. O

3 O
Inhibiting O
the O
growth O
of O
Staphylococcus B-PHE
aureus I-PHE
and O
Bacillus B-PHE
dysenteriae I-PHE
. O

-DOCSTART- O


discharge O
heat B-PHE
and O
cool O
blood B-PHE

-DOCSTART- O


Its O
decoction O
inhibits O
the O
development O
of O
egg-white O
induced O
arthritis B-PHE
in O
mice O
. O

-DOCSTART- O


calm O
five B-PHE
viscera I-PHE

-DOCSTART- O


Stage O
IV O
Childhood B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


move O
wind B-PHE
Gi(Qi O
) O

-DOCSTART- O


nocturnal B-PHE
emission I-PHE
; O
emission B-PHE
; O
spermatorrhea B-PHE
; O
seminal B-PHE
emission I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body O
weight O
regulation O
, O
Woman O
, O
Reproductive B-PHE
systems I-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Endocrine O
& O
reproductive B-PHE
systems I-PHE
, O
Intelligence O
, O
Dermatological B-PHE
systems I-PHE
health O
, O
Eldery O
, O
Overall O
CVD O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
General O
woman O
, O
General O
skin B-PHE
health I-PHE
, O
menopausal B-PHE
woman I-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


To O
reinforce O
qi O
and O
invigorate O
the O
function O
of O
the O
spleen B-PHE
and O
the O
lung B-PHE
. O

-DOCSTART- O


To O
remove O
damp-heat B-PHE
, O
quench O
fire B-PHE
and O
counteract O
toxicity B-PHE
. O

-DOCSTART- O


Treatment O
of O
mass B-PHE
in O
the O
abdomen O
, O
goitre B-PHE
with O
pain B-PHE
, O
epigastric B-PHE
pain I-PHE
and O
distension B-PHE
due O
to O
indigestion B-PHE
. O

-DOCSTART- O


The O
ingredients O
of O
this O
prescription O
are O
all O
bitter O
in O
taste O
and O
cold O
in O
nature O
, O
so O
that O
the O
fire O
purging O
and O
detoxifying O
effect O
is O
very O
strong O
. O

Since O
the O
bitter-cold O
drugs O
are O
liable O
to O
damage O
yin-energy O
, O
the O
prescription O
is O
only O
used O
for O
cases O
when O
the O

-DOCSTART- O


relaxing O
apoplexy B-PHE

-DOCSTART- O


invigorate O
blood B-PHE
and O
resolve O
stasis B-PHE

-DOCSTART- O


Woman O
, O
Eye B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Menopausal B-PHE
woman I-PHE
, O
Eye B-PHE
health I-PHE
, O
Lipid B-PHE
profile I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
sleep B-PHE
, O
Inflammation B-PHE
, O
Other O
system B-PHE
health I-PHE
, O
Memory B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
post O
delivery O
, O
Hypersensitivity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Quality O
of O
life O
, O
Eye B-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Blood B-PHE
pressure I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Diet B-PHE
cardiovascular I-PHE
disease I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Liver B-PHE
, O
Others O
, O
vigilance B-PHE
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Homocysteine B-PHE
metabolism I-PHE
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
activation B-PHE
, O
attention B-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Liver B-PHE
health I-PHE
, O
Eldery O
, O
Strength B-PHE
and O
power B-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Intelligence B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Overall O
CVD B-PHE
, O
General O
woman O
, O
General O
skin B-PHE
health I-PHE
, O
Strength B-PHE
and O
power B-PHE
Reproductive I-PHE
systems I-PHE
, O
Arousal B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Man O
, O
sleep B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
stanch O
bleeding B-PHE
and O
disperse O
swelling B-PHE
, O
kill O
worms B-PHE
. O

-DOCSTART- O


CYT006-AngQb O
is O
a O
therapeutic O
vaccine O
designed O
to O
instruct O
the O
patient's O
immune B-PHE
system I-PHE
to O
produce O
a O
specific O
anti-angiotensin B-PHE
II I-PHE
antibody I-PHE
response I-PHE
. O

-DOCSTART- O


Metabolic O
urinary O
profiling O
of O
alcohol B-PHE
hepatotoxicity I-PHE
and I-PHE
intervention I-PHE
effects O
of O
Yin O
Chen O
Hao O
Tang O
in O
rats O
using O
ultra O
- O
performance O
liquid O
chromatography O
/ O
electrospray O
ionization O
quadruple O
time O
- O
of O
- O
flight O
mass O
spectrometry O
. O

-DOCSTART- O


Insulin O
glargine O
is O
is O
a O
long-acting O
basal O
insulin O
analogue O
and O
binds O
to O
the O
insulin O
receptor O
, O
the O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

Insulin O
glulisine O
is O
a O
biosynthetic O
, O
rapid-acting O
human O
insulin O
analogue O
which O
differs O
from O
native O
human O
insulin O
in O
that O
the O
amino O
acid O
arginine O
at O
position O
B3 O
is O
replaced O
by O
lysine O
and O
the O
lysine O
at O
position O
B29 O
is O
replaced O
by O
glutamic O
acid O
. O

-DOCSTART- O


Menstrual B-PHE
disorder I-PHE
, O
postpartum B-PHE
abdominal I-PHE
pain I-PHE
due O
to O
stasis B-PHE
obstruction I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
wind-damp B-PHE
impediment I-PHE
pain I-PHE
. O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
and O
disinhibit O
damp B-PHE
. O

-DOCSTART- O


the O
upper O
emaciation B-PHE
; O
lung B-PHE
diabetes I-PHE

-DOCSTART- O


wind B-PHE
Pi I-PHE
syndrome I-PHE
; O
arthralgia B-PHE
due O
to O
wind B-PHE
arthritis I-PHE
mainly O
due O
to O
pathogenic B-PHE
wind I-PHE
, O
marked O
by O
swelling B-PHE
and O
migratory B-PHE
pain I-PHE
in O
the O
joints O
of O
the O
limbs O
. O

-DOCSTART- O


reinforce O
the O
kidney B-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
pricking B-PHE
pain I-PHE
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O


Complicated O
Skin O
and O
Skin B-PHE
Structure I-PHE
Infections I-PHE

-DOCSTART- O


Macular B-PHE
Degeneration I-PHE

-DOCSTART- O


For O
the O
treatment O
and O
management O
of O
congestive B-PHE
cardiac I-PHE
insufficiency I-PHE
, O
arrhythmias B-PHE
and O
heart B-PHE
failure I-PHE
. O

-DOCSTART- O


Pseudoephedrine O
relaxes O
bronchial B-PHE
smooth I-PHE
muscle I-PHE
by O
stimulating O
beta2-adrenergic O
receptors O
. O

-DOCSTART- O


Treament O
of O
looseness B-PHE
of I-PHE
teeth I-PHE
, O
premature B-PHE
greying I-PHE
of I-PHE
hair I-PHE
and I-PHE
beard I-PHE
, O
dizziness B-PHE
, O
tinnitus B-PHE
, O
aching B-PHE
and I-PHE
weakness I-PHE
of I-PHE
the I-PHE
loins I-PHE
and I-PHE
knees I-PHE
, O
spitting B-PHE
of I-PHE
blood I-PHE
, O
epistaxis B-PHE
, O
hematuria B-PHE
and O
diarrhea B-PHE
with O
bloody B-PHE
stools I-PHE
due O
to O
heat B-PHE
in I-PHE
the I-PHE
blood I-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
. O

-DOCSTART- O


reinforce O
blood B-PHE

-DOCSTART- O


Serious O
heat B-PHE
in O
lung O
and O
stomach O
, O
epidemic B-PHE
infectious I-PHE
diseases I-PHE
, O
fever B-PHE
, O
dizziness B-PHE
, O
aching B-PHE
of O
limbs O
, O
cough B-PHE
with O
copious B-PHE
phlegm I-PHE
, O
sore B-PHE
throat I-PHE
, O
epistaxis B-PHE
, O
haemoptysis B-PHE
, O
dryness B-PHE
of I-PHE
mouth I-PHE
and I-PHE
tongue I-PHE
. O

-DOCSTART- O


This O
is O
a O
symptom O
with O
a O
pain B-PHE
in O
a O
waist O
and O
the O
side O
. O

-DOCSTART- O


( O
1 O
) O
precordial B-PHE
pain I-PHE
; O
intermittent O
cardiac B-PHE
pain I-PHE
( O
2 O
) O
epigastric B-PHE
pain I-PHE

-DOCSTART- O


fluid B-PHE
retention I-PHE
; O

phlegm B-PHE
and O
retained B-PHE
fluid I-PHE
; O

congested B-PHE
fluids I-PHE

-DOCSTART- O


hematuria B-PHE
with I-PHE
pain I-PHE
; O
stranguria B-PHE
with I-PHE
hematuria I-PHE
; O
painful O
urination B-PHE
with I-PHE
blood I-PHE

-DOCSTART- O


abortion B-PHE

-DOCSTART- O


Purging O
by O
pressure O
and O
by O
removing O
liquid O

-DOCSTART- O


1 O
Application O
to O
cass O
of O
early O
stage O
of O
superficial O
pyogenic O
infection O
with O
local O
signs O
of O
inflammation B-PHE
, O
chilliness B-PHE
, O
fever B-PHE
, O
bitter B-PHE
mouth I-PHE
, O
constipation B-PHE
, O
oliguria B-PHE
, O
red B-PHE
tongue I-PHE
with O
white O
fur O
and O
rapid B-PHE
pulse I-PHE
. O
2 O
Also O
indicated O
for O
cases O
of O
urticaria B-PHE
and O
e O

-DOCSTART- O


To O
activate O
blood B-PHE
circulation I-PHE
, O
eliminate O
stasis B-PHE
, O
promote O
the O
subsidence B-PHE
of I-PHE
swelling I-PHE
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


To O
clear O
liver B-PHE
and O
brighten O
eyes B-PHE
. O

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
cardiovascular B-PHE
disorders I-PHE
and O
inflammatory B-PHE
disorders I-PHE
( O
unspecified O
) O
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


pricking B-PHE
pain I-PHE

-DOCSTART- O


Weak O
stomach O
qi O
, O
noise B-PHE
in I-PHE
stomach I-PHE
, O
diarrhea B-PHE
, O
stagnation B-PHE
of I-PHE
water I-PHE
, O
dry B-PHE
vomiting I-PHE
, O
annoyment B-PHE

-DOCSTART- O


Infant B-PHE
, I-PHE
Newborn I-PHE
, I-PHE
Diseases I-PHE

-DOCSTART- O


Besifloxacin O
is O
a O
bactericidal O
fluroquinolone-type O
antibiotic O
that O
inhibits O
bacterial B-PHE
enzymes I-PHE
, O
DNA B-PHE
gyrase I-PHE
and O
topoisomerase B-PHE
IV I-PHE
. O

By O
inhibiting O
DNA B-PHE
gyrase I-PHE
, O
DNA B-PHE
replication O
, O
transcription O
, O
and O
repair O
is O
impaired O
. O

By O
inhibiting O
topoisomerase B-PHE
IV I-PHE
, O
decatenation O
during O
cell O
devision O
is O
impaired O
. O

Inhibiting O
these O
two O
targets O
also O
slows O
down O
development O
of O
resistance O
. O

-DOCSTART- O


convulsive B-PHE
disease I-PHE
; O
epilepsy B-PHE
induced O
by O
frightening O

-DOCSTART- O


Specifically O
, O
dalbavancin O
prevents O
incorporation O
of O
N-acetylmuramic B-PHE
acid I-PHE
( O
NAM B-PHE
) O
- O
and O
N-acetylglucosamine B-PHE
( O
NAG B-PHE
) O
- O
peptide O
subunits O
from O
being O
incorporated O
into O
the O
peptidoglycan O
matrix O
; O
which O
forms O
the O
major O
structural O
component O
of O
Gram-positive O
cell O
walls O
. O

-DOCSTART- O


